ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer – Update 2023*

David Cibula,1,2 Maria Rosaria Raspollini,3 François Planchamp,4,5 Carlos Centeno,5 Cyrus Chargari,6 Ana Felix,7,10 Daniela Fischerová,8,9,12 Daniela Jahnn-Kuch,9 Florence Joly,10 Christhardt Kohler,11,12 Sigurd Lax,13,14 Domenica Lorusso,15,16 Umesh Mahantshetty,17 Patrice Mathevet,18 Raj Naik,19 Remi A Noui,20,21 Ana Oaiknin,22,23 Pedro Peccatori,24 Jan Persson,25,26 Denis Querleu,15,27 Sandra Rubio Bernabé,28 Maximilian P Schmid,29 Artem Stepanyan,30 Valentyn Svintsitskyi,31 Karl Tamussino,32 Ignacio Zapardiel,33 Jacob Lindegaard34

ABSTRACT

In 2018, the European Society of Gynecological Oncology (ESGO) jointly with the European Society for Radiotherapy and Oncology (ESTRO) and the European Society of Pathology (ESP) published evidence-based guidelines for the management of patients with cervical cancer. Given the large body of new evidence addressing the management of cervical cancer, the three sister societies jointly decided to update these evidence-based guidelines. The update includes new topics to provide comprehensive guidelines on all relevant issues of diagnosis and treatment in cervical cancer.

To serve on the expert panel (27 experts across Europe) ESGO/ESTRO/ESP nominated practicing clinicians who are involved in managing patients with cervical cancer and have demonstrated leadership through their expertise in clinical care and research, national and international engagement, profile, and dedication to the topics addressed. To ensure the statements were evidence based, new data identified from a systematic search was reviewed and critically appraised. In the absence of any clear scientific evidence, judgment was based on the professional experience and consensus of the international development group. Before publication, the guidelines were reviewed by 155 independent international practitioners in cancer care delivery and patient representatives. These updated guidelines are comprehensive and cover staging, management, follow-up, long-term survivorship, quality of life and palliative care. Management includes fertility sparing treatment, early and locally advanced cervical cancer, invasive cervical cancer diagnosed on a simple hysterectomy specimen, cervical cancer in pregnancy, rare tumors, recurrent and metastatic diseases. The management algorithms and the principles of radiotherapy and pathological evaluation are also defined.

INTRODUCTION

Cervical cancer is a major public health problem, ranking as the fourth most common cause of cancer incidence and mortality in women worldwide. There are geographical variations in cervical cancer that reflect differences particularly in the prevalence of human papillomavirus (HPV) infection and inequalities in access to adequate screening and treatment.1 Cervical cancer is uncommon in Europe but still remains the most frequent cause of cancer death in middle-aged women in Eastern Europe.2 Other epidemiologic risk factors associated with cervical cancer are notably a history of smoking, oral contraceptive use, early age of onset of coitus, number of sexual partners, history of sexually transmitted disease, certain autoimmune diseases, and chronic immunosuppression. Squamous cell carcinomas account for approximately 80% of all cervical cancers and adenocarcinoma accounts for approximately 20%. The WHO recently launched a global initiative to scale up preventive, screening, and treatment interventions relying on vaccination against HPVs, screening and treatment of detected cervical pre-invasive and invasive lesions, and offering the best possible curative care to women diagnosed with invasive cancer.3

As part of its mission to improve the quality of care for women with gynecological cancers across Europe, in 2018 the European Society of Gynecological Oncology (ESGO) jointly with the European Society for Radiotherapy and Oncology (ESTRO) and the European Society of Pathology (ESP) published evidence-based guidelines to improve the management of patients with cervical cancer within a multidisciplinary setting.4-8 Given the large body of new evidence addressing the management of cervical cancer, the three sister societies jointly decided to update these evidence-based guidelines and to include new topics in order to provide comprehensive guidelines on all relevant issues of diagnosis and treatment in cervical cancer. These guidelines are intended for use by

*Correspondence to
Dr David Cibula, Department of Obstetrics and Gynecology, Charles University, First Faculty of Medicine, Prague, 121 08, Czech Republic; dc@ davidcibula.cz

For ‘Presented at statement’ see end of article.

Received 28 February 2023
Accepted 30 March 2023
Published Online First
26 April 2023

© ESGO, ESTRO, ESP 2023.
Published by BMJ, Elsevier, and Springer. This is an open access article under the CC BY license.

gynecological oncologists, general gynecologists, surgeons, radiation oncologists, pathologists, medical and clinical oncologists, radiologists, general practitioners, palliative care teams, and allied health professionals.

RESPONSIBILITIES

Even though our aim is to present the highest standard of evidence in an optimal management of patients with cervical cancer, ESGO, ESTRO, and ESP acknowledge that there will be broad variability in practices between the various centers worldwide. Moreover, there will also be significant differences in infrastructure, access to medical and surgical technology, and also training, medicolegal, financial, and cultural aspects that will affect the implementation of any guidelines. These guidelines are a statement of evidence and consensus of the multidisciplinary development group regarding their views and perspective of currently accepted approaches for the management of patients with cervical cancer. Any clinician applying or consulting these guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. These guidelines make no representations or warranties of any kind whatsoever regarding their content, use, or application and disclaim any responsibility for their application or use in any way.

METHODS

The guidelines were developed using a five-step process defined by the ESGO Guideline Committee (see Figure 1). The strengths of the process include creation of a multidisciplinary international development group, use of scientific evidence and international expert consensus to support the guidelines, and use of an international external review process (physicians and patients). This development process involved three meetings of the international development group, chaired by Professor David Cibula (First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic), Professor Jacob Christian Lindegaard (Aarhus University Hospital, Aarhus, Denmark), and Professor Maria Rosaria Raspollini (University of Florence, Florence, Italy).

To serve on the expert panel, ESGO/ESTRO/ESP nominated practicing clinicians who are involved in managing patients with cervical cancer and have demonstrated leadership through their expertise in clinical care and research, national and international engagement and profile as well as dedication to the topics addressed. The objective was to assemble a multidisciplinary development group and it was therefore essential to include professionals from relevant disciplines (gynecological oncology and gynecology, medical, clinical and radiation oncology, pathology) to contribute to the validity and acceptability of the guidelines. To ensure that the statements were evidence based, the current literature was reviewed and critically appraised. A systematic, unbiased literature review of relevant studies published between January 2017 and March 2022 was carried out using the MEDLINE database (see Online Supplemental File 2). The literature search was limited to publications in English. Priority was given to high-quality systematic reviews, meta-analyses, and randomized controlled trials, but studies of lower levels of evidence were also evaluated. The search strategy excluded editorials, letters, and in vitro studies. The reference list of each identified article was reviewed for other potentially relevant articles. Based on the collected evidence and clinical expertise, the international development group drafted guidelines for all the topics. The updated guidelines were retained if they were supported by a sufficiently high level of scientific evidence and/or when a large consensus among experts was obtained. An adapted version of the “Infectious Diseases Society of America–United States Public Health Service Grading System was used to define the level of evidence and grade of recommendation for each of the recommendations” (see Figure 2). In the absence of any clear scientific evidence, judgment was based on the professional experience and consensus of the international development group.

ESGO/ESTRO/ESP established a large multidisciplinary panel of practicing clinicians who provide care to patients with cervical cancer to act as independent reviewers for the updated guidelines. These reviewers were selected according to their expertise, had to be still involved in clinical practice/research, and were from different European and non-European countries to ensure a global perspective. Patients with cervical cancer were also included. The independent reviewers were asked to evaluate each recommendation according to its relevance and feasibility in clinical practice (only physicians), so that comprehensive quantitative and qualitative evaluations of the updated guidelines were completed. Patients were asked to evaluate qualitatively each recommendation (according to their experience, personal perceptions, etc.). Evaluations of the external reviewers (n=155) were pooled and discussed by the international development group to finalize the guidelines’ updating process. The list of the 155 external reviewers is available in Online Supplemental File 2.

GUIDELINES

The guidelines detailed in this article cover staging, management, follow-up, long-term survivorship, quality of life and palliative care. Management includes fertility sparing treatment, early and locally
advanced cervical cancer, invasive cervical cancer diagnosed on a simple hysterectomy (SH) specimen, cervical cancer in pregnancy, rare tumors, recurrent and metastatic diseases. A summary of evidence supporting the guidelines is included in Online Supplemental File 1, available online.

General Recommendations
► Centralization of care in specialized centers and referral network is encouraged [IV, B].
► Treatment planning should be made on a multidisciplinary basis (generally at a tumor board meeting as defined in the ESGO quality indicators) and based on the comprehensive and precise knowledge of prognostic and predictive factors for oncological outcome, side effects, and quality of life [IV, A].
► Patients should be carefully counseled on the suggested treatment plan and potential alternatives, including risks and benefits of all options [V, A].
► Treatment should be undertaken by a dedicated team of specialists in the diagnosis and management of cervical cancers [IV, A].
► Enrollment of patients with cervical cancer in clinical trials is encouraged [V, B].

Staging
TNM Classification and FIGO Staging
► Patients with cervical cancer should be staged according to the TNM classification and the International Federation of Gynecology and Obstetrics (FIGO) staging should also be documented [IV, A].
► Systematic documentation and integration of the results from clinical examination, pathology and imaging including multidisciplinary team discussions of disparate findings is recommended [IV, A].

Prognostic Factors
► Systematic documentation of the following major tumor-related prognostic factors is recommended [II, A]:
► TNM and FIGO stage, including a maximum tumor size, detailed description of extracervical tumor extension (including uterine corpus involvement) and nodal involvement (eg, total number, location, size, and metabolic activity).
► Pathological tumor type including HPV status (see principles of pathological evaluation).
► Depth of cervical stromal invasion and a minimum thickness of uninvolved cervical stroma
► Margin status (ectocervical, endocervical, radial/deep stromal and vaginal cuff)
► Presence or absence of lymphovascular space involvement (LVI).
► Presence or absence of distant metastases.

Local Clinical and Radiological Diagnostic Work-up
► Pelvic examination and biopsy±colposcopy are mandatory to diagnose cervical cancer [II, A].
► Pelvic magnetic resonance imaging (MRI) is mandatory for initial assessment of pelvic tumor extent and to guide treatment options (optional for T1a tumor with free margins after conization). Endovaginal/transrectal ultrasonography is an option if performed by a properly trained sonographer [II, A].
► Cystoscopy or proctoscopy are not routinely recommended [IV, D].
Nodal/Distant Diagnostic Work-up
► In early stages managed primarily by surgery, surgical/pathological staging of pelvic lymph node (PLN) is the standard criterion to assess the prognosis and to guide treatment (except for T1a1 and T1a2 without LVI) [III, A].
► In locally advanced cervical cancer (T1b3 and higher (except T2a1) or in early-stage disease with suspicious LN on imaging), positron emission tomography-computed tomography (PET-CT), or chest/abdomen computed tomography (CT scan) (if PET-CT is not available) is recommended for assessment of nodal and distant disease [III, B].
► PET-CT is recommended before chemoradiotherapy (CTRT) with curative intent [III, B].
► Para-aortic LN dissection (PALND), at least up to inferior mesenteric artery, may be considered in locally advanced cervical cancer with negative para-aortic LN on imaging for staging purposes [IV, C].
► Equivocal extrauterine disease should be considered for biopsy to avoid inappropriate treatment [IV, B].

Management of T1a Disease
Diagnosis of T1a Disease
► Diagnosis of T1a cancer should be based on a conization (or excision) specimen examined by an expert pathologist with accurate measurement of depth of invasion, margin status, coexisting pathology, and reliable assessment of LVI [IV, B].
► Loop or laser conization is preferable to cold-knife conization in women wanting to preserve fertility. Care should be taken to provide an intact (unfragmented) specimen with minimal thermal artifact. The cone specimen should be oriented for the pathologist [IV, B].
► Surgical margins of the cone specimen should be clear of both invasive and preinvasive disease (except for low-grade intraepithelial lesion) [IV, B].

Management of T1a1 Disease
► Management of patients with T1a1 disease should be tailored to the individual depending on age, desire for fertility preservation, histological type, and the presence or absence of LVI [III, B].
► In case of positive margins (except for low-grade intraepithelial lesion in ectocervix), a repeat conization should be performed to rule out more extensive invasive disease [IV, B].
► LN staging is not indicated in T1a1 LVI-negative patients but can be considered in T1a1 LVI-positive patients. Sentinel lymph node (SLN) biopsy (without additional PLN dissection (PLND)) is recommended in this situation [IV, B].
► Conization can be considered a definitive treatment as hysterectomy does not improve the outcome [IV, C].
► Radical surgical approaches such as radical hysterectomy, trachelectomy or parametrectomy represent overtreatment and should not be performed for patients with T1a1 disease [IV, D].
► Patients with T1a1 adenocarcinoma who have completed childbearing should be offered SH [IV, B].

Management of T1a2 Disease
► Conization (with clear margins) alone or SH is an adequate treatment for patients with T1a2 disease [IV, B].
► Parametrial resection is not indicated [IV, D].
► SLN biopsy (without additional PLND) can be considered in LVI-negative patients but should be performed in LVI-positive patients [IV, B].
► Patients with T1a2 adenocarcinoma who have completed childbearing should be offered SH [IV, B].

Management of T1b1, T1b2, and T2a1 Tumors
General Recommendations
► Treatment strategy should aim to avoid combining radical surgery and radiotherapy because of the high morbidity induced by the combined treatment [IV, A].

Negative LN on Radiological Staging - Surgical Treatment
► Radical surgery by a gynecological oncologist is the preferred treatment modality. Laparotomy is the standard approach for all procedures which include radical parametrectomy [I, A].
► Minimally invasive approach may be considered only in low risk tumors (<2 cm and free margins after conization), in high-volume centers experienced in performing radical hysterectomy with minimally invasive surgery, which meet the ESGO quality criteria for surgery, if the patient agrees after comprehensive discussion about current evidence [IV, C].
► LN assessment should be performed as the first step of surgical management [IV, A]. Minimally invasive surgery is an acceptable approach for LN staging [IV, B].
► SLN biopsy before pelvic lymphadenectomy should be performed. Indocyanine green is the preferred technique [III, A]. A combination of blue dye with radiocolloid is an alternative technique [IV, B].
► Intra-operative assessment of LN status (evaluated by frozen section) is recommended. Sentinel nodes from both sides of the pelvis and/or any suspicious LN should be sent for intra-operative assessment [III, A].
► If any LN involvement is detected intraoperatively, further PLND and radical hysterectomy should be avoided. Patients should be referred for definitive CTRT [III, A]. PALND at least up to inferior mesenteric artery may be considered for staging purposes [IV, C].
► After SLN biopsy, if SLN are negative on frozen section, a systematic pelvic lymphadenectomy should be performed as the standard LN staging [III, A].
► If SLN is negative bilaterally in the pelvic level I area (below iliac bifurcation) LN dissection can be limited to level I [IV, B].
► If SLN is not detected on either side, LN dissection should include on that particular pelvic side the removal of lymphatic tissue from all traditional regions including obturator fossa, external iliac regions, common iliac regions, and presacral region [III, A].
► After frozen section, all SLN should be processed according to pathological protocol for ultrastaging (see the principles of pathological evaluation) [III, A].
► The type of radical hysterectomy (extent of parametrial resection, type A-C2) should be based on the presence of prognostic risk factors identified preoperatively such as tumor size, maximum stromal invasion, and LVI, which are used to categorize patients at high, intermediate, and low risk of treatment.
failure. A complete description of the template used for radical hysterectomy should be present in the surgical report. The 2017 modification of the Querleu-Morrow classification is recommended as a tool [IV, A].

- Ovarian preservation should be discussed with women in reproductive age with squamous cell carcinoma, can be considered in HPV-associated adenocarcinoma and is not recommended for HPV-independent adenocarcinomas. Opportunistic bilateral salpingectomy should be performed if ovaries are preserved. Ovarian transposition should be discussed upfront with the patient and individualized according to risk balance [IV, A].
- If a combination of risk factors is known at diagnosis, which would require an adjuvant treatment, definitive CTRT and brachytherapy (BT) should be considered without previous radical pelvic surgery [IV, A].

Negative LN on Radiological Staging – Alternative Treatment Options

- Definitive CTRT and image-guided brachytherapy (IGBT) represent an alternative treatment option [IV, B].
- Neoadjuvant chemotherapy (NACT) or CTRT followed by surgery are not recommended [IV, D].

Adjuvant Treatment After Radical Surgery

- Adjuvant radiotherapy should be considered in the intermediate risk group (combination of risk factors at final pathology such as tumor size, LVSI, and depth of stromal invasion) [IV, A].
- When an adequate type of radical hysterectomy has been performed in intermediate risk group patients, observation is an alternative option, especially in teams experienced in this approach [IV, B].
- Adjuvant CTRT is indicated in the high-risk group (see principles of radiotherapy) [IV, A]:
  - metastatic involvement of PLN (macrometastases pN1 or micrometastases pN1(mi)) on final pathologic assessment.
  - positive surgical margins (vagina/parametria/paracervix).
  - parametrial involvement.
- Additional BT boost as part of adjuvant CTRT can be considered in cases with vaginal and/or parametrial positive disease (see principles of radiotherapy) [IV, B].
- Adjuvant treatment may be considered also if only isolated tumor cells are detected in SLN, although its prognostic impact remains uncertain [IV, C].

Fertility Sparing Treatment

- Fertility-sparing treatment is an oncologically valid alternative to radical hysterectomy for young patients with cervical cancer <2 cm (squamous cell carcinoma and HPV-related adenocarcinoma) who want to preserve the option to have children. Before initiating fertility sparing therapy, consultation at an onco-fertility center and discussion in a multidisciplinary tumor board is recommended [III, B].
- Counseling of eligible patients should encompass the oncologic and obstetric risks related to this type of management as well as the risk of fertility sparing therapy abandonment if there are positive resection margins or LN involvement [III, A].
- Fertility-sparing treatment should be performed exclusively in gynaecological-oncological centers with comprehensive expertise in all types of these surgical procedures [IV, A].
- Fertility-sparing treatment should not be recommended for uncommon and rare histological types/subtypes of cervical cancer with aggressive behavior including neuroendocrine carcinomas, HPV-independent adenocarcinomas and carcinosarcomas [V, D].
- For patients who consider fertility sparing therapy, prognostic factors, clinical staging, and preoperative work-up do not differ from those not considering fertility sparing therapy (see above). Pelvic MRI and/or expert sonography are mandatory imaging tests to measure the non-involved cervical length (upper tumor free margin) and the remaining (after cone biopsy) cervical length [III, A].
- Negative PLN status is the precondition for any fertility sparing therapy. Therefore, PLN staging (SLN) should always be the first step in each fertility-sparing therapy procedure. Identification of SLN and its ultrastaging is highly recommended. Any intraoperative suspicious LN (apart from SLN) should also be removed if SLN cannot be detected on either pelvic side, a systematic pelvic lymphadenectomy should be performed on that side. Intraoperative assessment of LN status is highly recommended. All SLN from both sides of the pelvis and any suspicious LN should be sent for frozen section. LN staging is not indicated in T1a1 LVSI negative [III, A].
- In case of intraoperatively proven PLN involvement, fertility-sparing surgery should be abandoned and patients should be referred for CTRT and BT [IV, B]. PALND, at least up to inferior mesenteric artery, may be considered for staging purposes [IV, C]. Ovarian transposition cannot be recommended in N1 status [IV, D].
- The specific goal of fertility-sparing surgery must be resection of invasive tumor with adequate free margins and preservation of the upper part of the cervix [IV, A]. Intraoperative frozen section is a feasible way of assessing the upper resection margin [IV, C].
- LN staging follows the principles of management of early stages [III, B].
- Fertility sparing procedures comprise of conization (see Figure 3), simple trachelectomy (see Figure 4), radical (vaginal)
trachelectomy (see Figure 5), abdominal radical trachelectomy (see Figure 6) [III, B].

- Conization and simple trachelectomy are adequate fertility sparing procedures in patients with T1a1 and T1a2 tumors, regardless of LVSI status [IV, B].
- Conization or simple trachelectomy are adequate fertility sparing procedures for T1b1, LVSI negative tumors. Radical trachelectomy is still an option [IV, B].
- Radical trachelectomy (type B) should be performed in patients with cervical cancer T1b1, LVSI-positive. In patients without deep stromal involvement and with a high probability of adequate endocervical tumor free margins, simple trachelectomy can be considered [III, B].
- Intraoperative placement of permanent cerclage should be performed during simple or radical trachelectomy [IV, B].
- Fertility sparing therapy for patients with tumors greater than 2 cm is significantly associated with a higher risk of recurrence and should not be considered as a standard treatment. The risk of recurrence must be comprehensively discussed with the patient. NACT followed by radical vaginal trachelectomy and abdominal radical trachelectomy or cone has been described for fertility sparing treatment in patients with tumors >2 cm. PLN staging should be performed before starting NACT to confirm tumor-free LN. The optimal number of chemotherapy cycles, chemotherapy regimen as well as extent of cervical resection following NACT, are still a matter of debate [IV, B].
- In more advanced cases, various fertility preservation proposals such as ovarian transposition (see Figure 7), oocyte-, embryo- or ovarian tissue preservation and egg donation should be discussed with the patient. The aim of the fertility preservation should be to offer the most efficient approach in accordance with the legal country-specific regulations, while not increasing the oncological risk [IV, B].
- Any pregnancy following fertility sparing therapy should be considered as a high-risk pregnancy. Following simple or radical trachelectomy with placement of a permanent cerclage, delivery can only be performed by cesarean section [IV, B].

![Figure 4 Simple trachelectomy.](image1)

![Figure 5 Radical (vaginal) trachelectomy.](image2)

![Figure 6 Abdominal radical trachelectomy.](image3)

![Figure 7 Ovarian transposition.](image4)
Surgical LN staging is recommended in patients with T1b1. Surgical LN assessment can be considered in T1a1 tumors in patients with T1a1 tumor regardless of LVSI status and Para-

Management of Patients with T1a1 and T1a2 Disease

In patients with T1a1 tumor regardless of LVSI status and T1a2 tumor LVSI negative with clear margins in the hysterectomy specimen, no additional treatment is recommended (III, B).

Surgical LN assessment can be considered in T1a1 tumors with LVSI and it should be performed in T1a2 LVSI positive cases (III, B).

Management of Patients with T1b1 Disease, with Clear Margins and Without Residual Tumor

Surgical LN staging is recommended in patients with T1b1 tumor with clear margins and absence of residual tumor on imaging (including non-suspicious LN). In case of histological evidence of PLN involvement, definitive CTRT is recommended and PALND, at least up to inferior mesenteric artery, may be considered for staging purposes (III, B).

In pathologically node negative patients with T1b1 disease, potential disease in the parametria should be addressed. Parametrectomy and upper vaginectomy should be considered (III, B).

Radiotherapy can be considered as an alternative modality to surgical treatment, considering the risk-benefit of repeat surgery (IV, C).

Management of Patients with ≥ T1b2 Disease, Involved Surgical Margins and/or Residual Tumor (Including LN)

For patients with free surgical margins and in the absence of residual tumor on imaging (including non-suspicious LN), (chemo)radiotherapy is recommended as a treatment that avoids further surgical management (IV, B).

Radical surgery (pelvic lymphadenectomy, parametrectomy and resection of the upper vagina) is an option in selected patients without expected indication for adjuvant (chemo)radiotherapy. If surgery has been performed, indications for adjuvant (chemo)radiotherapy follow the general recommendations (IV, B).

If there is residual tumor on imaging (including suspicious LN), or involved surgical margins, CTRT with or without BT is the treatment of choice (see principles of radiotherapy) (III, B). Para-aortic LN dissection, at least up to inferior mesenteric artery, may be considered for staging purposes in patients with positive pelvic nodes and negative paraaortic LN on imaging (IV, C).

Management of Locally Advanced Cervical Cancer (T1b3-T4a)

Definitive radiotherapy should include concomitant chemo-
therapy whenever possible (I, A).

IGBT is an essential component of definitive radiotherapy and should not be replaced with an external boost (photon or proton). If BT is not available, patients should be referred to a center where this can be done (III, B).

General recommendations for prescription of CTRT and IGBT are as follows (details given in the section on principles of radiotherapy) (III, B):

- 3D imaging (preferentially both MRI and (PET-CT) with the patient in the treatment position should be used for target contouring.

- It is recommended to deliver external beam radiotherapy (EBRT) with a dose of 45 Gy/25 fractions or 46 Gy/23 fractions by use of intensity-modulated or volumetric arc technique.

- Additional dose of radiation should be applied to pathological LN on imaging, preferentially using a simultaneous integrated boost (60 Gy EQD2, combined EBRT and estimated dose from IGBT).

- Concomitant weekly cisplatin is standard. However, weekly carboplatin or hyperthermia can be considered as an alternative option for patients not suitable for cisplatin.

- Image-guided adaptive brachytherapy (IGABT) (preferentially MRI) including access to intracavitary/interstitial techniques are needed to obtain a sufficiently high dose to ensure a high rate of local control in advanced cases with poor response to initial CTRT. This is especially important for non-squamous histology.
Original research

- Boosting of the primary tumor and/or the parametria by use of EBRT should be avoided.
- The overall treatment time including both CTRT and IGBT should aim to not exceed 7 weeks.

► PALND (at least up to inferior mesenteric artery) may be used to assess the need for elective para-aortic EBRT in patients with negative para-aortic lymph nodes (PALN) and positive PLN on imaging [IV, C].

► If PALND is not performed, risk assessment for microscopic para-aortic nodal involvement and the indication for elective para-aortic irradiation can be based on the number of level 1 positive nodes (external iliac, interilac, internal iliac) on imaging (e.g. ≥2 positive nodes). However, elective para-aortic radiation should always be applied in patients who on imaging have even one positive node at level 2 (common iliac) and above. The groin should also be included in the elective target for patients with tumor involvement of the lower-third of the vagina [IV, B].

► Surgical removal of large pathological pelvic and/or para-aortic nodes before definitive CTRT is not routinely recommended [IV, D].

► NACT in patients who otherwise are candidates for upfront definitive CTRT and IGBT is not recommended outside of clinical trials [II, D].

► Adjuvant chemotherapy following definitive CTRT and IGBT does not improve survival and enhances toxicity and should not be used outside clinical trials [IV, D].

► Adjuvant/completion hysterectomy after definitive CTRT and IGBT should not be performed since it does not improve survival and is associated with both increased perioperative and late morbidities [II, E].

► Patients with a persistent tumor 3–6 months after definitive CTRT and BT and without evidence of regional or metastatic disease should be referred to specialized centers for evaluating the necessity and the possibility of performing salvage surgery (see management of recurrent disease and follow-up sections) [IV, B].

Role of Surgery in T1B3 and T2a2 (LN Negative) Tumors

► There is limited evidence to guide the choice between surgical treatment vs CTRT with IGBT in LN negative patients with T1b3 and T2a2 tumors. Histology, tumor size, completeness of the cervical rim, uterine corpus invasion, magnitude of vaginal invasion, age, comorbidity, menopausal status, body mass index, hemoglobin and experience with type C radical hysterectomy are some of the factors to consider [IV, B].

► For surgery, avoidance of the combination of radical surgery and post-operative external radiotherapy requires acceptance for modifications of the traditional selection criteria (tumor size, degree of invasion, LVS) for adjuvant treatment [IV, B].

► The patient should be discussed in a multidisciplinary team and should be counseled for the advantages and disadvantages of both treatment options (surgery vs radiotherapy) in relation to the individual presence of prognostic factors [IV, A].

► Given the limited number of patients with T1b3 and T2a2 (<10%) tumors, referral to highly specialized centers for treatment is recommended [IV, A].

► Type C radical hysterectomy is recommended. LN staging should follow the same principles as in T1b1-2 tumors [IV, A].

► NACT followed by radical surgery should not be performed outside clinical trials [I, E].

Recurrent/Metastatic Disease

General Recommendations

► Treatment of recurrent disease requires centralization and involvement of a broad multidisciplinary team including a gynecological oncologist, radiation oncologist, radiologist, pathologist, medical oncologist, urologist, and plastic surgeon. A structured program for multidisciplinary diagnostic work-up, treatment, and follow-up must be present in centers responsible for the treatment [IV, A].

► Participation in clinical trials is encouraged [V, B].

► Early involvement of a palliative care specialist is encouraged [V, B].

► The patient should be carefully counseled regarding treatment options, risks and consequences [V, A].

Diagnostic Work-up

► The aim of the diagnostic work-up is to determine the extent of the locoregional and/or metastatic disease [V, B].

► The recurrence should be confirmed by histological examination if feasible [IV, B].

► Patients with multiple nodal/distant metastases (i.e., not oligometastatic disease) or multifocal local disease with extensive pelvic wall involvement should not be considered as candidates for radical treatment [IV, D].

► Patients with oligometastatic or oligorecurrent disease should be considered for radical and potentially curative treatment options [IV, B].

► The prognostic factors should be evaluated carefully and balanced in relation to the major morbidity caused by the treatment [IV, A].

Locoregional Recurrent Disease - Central Pelvic Recurrence After Primary Surgery

► Definitive CTRT combined with IGABT is the treatment of choice in radiotherapy naïve patients [IV, A]. The use of boost by external beam techniques to replace IGBT is not recommended [IV, D].

► Small superficial lesions (i.e., <5 mm thickness) in the vagina may be treated by IGBT using a vaginal cylinder, ovoids, or mold, whereas other lesions usually require combined intracavitary-interstitial techniques [IV, C].

Locoregional Recurrent Disease - Pelvic Sidewall Recurrence After Primary Surgery

► Definitive CTRT is the preferred option in radiotherapy naïve patients [IV, A].

► When radical radiotherapy is not feasible, extended pelvic surgery can be considered. Surgery must aim for a complete tumor resection (R=0) also with the help of special techniques (laterally extended endopelvic resection (LEER), out of box procedures), if required [IV, B].

► Combined operative-radiotherapy procedures using intraoperative radiotherapy or IGBT are an option if free surgical margins are not achievable [IV, B].
Locoregional Recurrent Disease - Central Pelvic or Pelvic Sidewall Recurrence After Radiotherapy

- Pelvic exenteration is recommended for central pelvic recurrence where there is no involvement of the pelvic sidewall, extrapelvic nodes or peritoneal disease [IV, B].
- Reirradiation with IGABT for central recurrences could be considered in selected patients taking into account volume of the disease, or time from the primary radiotherapy and total dose administered initially. This must be performed only in specialized centers [IV, C].
- In patients with pelvic sidewall involvement, extended pelvic surgery can be considered in specialized centers. Surgery must aim for a complete tumor resection (R=0) also with the help of special techniques (LEER, out of box procedures), if required [IV, B].
- Patients who are not candidates for extensive surgery should be treated with systemic chemotherapy. Additional treatment can be considered depending on the response [IV, B].

Oligometastic Recurrences

- Localized para-aortic, mediastinal, and/or peri-clavicular recurrences out of previously irradiated fields may be treated by radical EBRT with or without chemotherapy [IV, C].
- The therapeutic effect of nodal resection/debulking is unclear and should, if possible, be followed by radiotherapy [IV, C].
- The management of “oligo” organ metastases (lung, liver, etc.) should be discussed in a multidisciplinary setting including the team involved in the treatment of the organ-affected metastasis. Treatment options are represented by local resection, thermal ablation, interventional BT, or stereotactic ablative radiotherapy according to the size and localization [IV, B].

Distant Recurrent and Metastatic Disease

- Patients with recurrent/metastatic disease should have a full clinical-diagnostic evaluation to assess the extent of disease and the most appropriate treatment modality including best supportive care [V, A].
- Platinum-based chemotherapy±bevacizumab is recommended for chemo-naïve, medically fit patients with recurrent/metastatic disease. Carboplatin/paclitaxel and cisplatin/paclitaxel are the preferred regimens [I, A].
- The addition of bevacizumab to platinum-based chemotherapy is recommended when the risk of significant gastrointestinal/genitourinary toxicities has been carefully assessed and discussed with the patient [I, A].
- The addition of pembrolizumab to platinum-based chemotherapy±bevacizumab is recommended in patients with PD-L1 positive tumors, assessed as combined positive score (CPS) of 1 or more [I, A].
- Patients who progressed after first-line platinum-based chemotherapy should be offered treatment with the anti PD-1 agent, cemiplimab, regardless of PDL-1 tumor status as long as they had not previously received immunotherapy [I, A].
- Patients with distant metastatic disease at diagnosis, who have responded to systemic chemotherapy, could be considered for additional radical pelvic radiotherapy (including IGBT in selected cases). Those with residual oligometastatic disease after systemic treatment could also be considered for additional regional treatment (surgery, thermal ablation, radiotherapy) to involved sites [IV, C].
- Inclusion of patients with recurrent/metastatic disease in clinical trials is strongly recommended [V, A].

Follow-up During and After Treatment/Long-term Survivorship

General Recommendations

- Patients should be informed and educated at the time of diagnosis and throughout follow-up about signs/symptoms of recurrence. They should be informed about possible side effects (by physicians, nurses, brochures, videos, etc.) [V, A].
- A network of healthcare providers including all care providers should be involved in the care of survivors (eg, primary care physicians, gynecologists, psychologists, sexologists, physiotherapists, dieticians, social workers) for the follow-up [V, A].
- Follow-up strategy should be individualized in terms of intensity, duration and procedures, taking into account individual risk assessment [V, A]. Available prognostic models, such as the Annual Risk Recurrence Calculator available on the ESGO website can be used to tailor surveillance strategy in an individual patient [IV, B].
- Follow-up should be centralized/coordinated in a center specialized in the treatment and follow-up of gynecological cancer patients [IV, A].
- Follow-up is designed to monitor disease response, to detect recurrence and to screen for subsequent primary tumors [V, B].
- Regular and systematic monitoring of side effects and quality of life should be performed to improve the quality of care [V, A].
- Prevention and early detection of immediate and persistent symptoms and side effects of the different cancer treatments and the individual patient supportive care needs should be identified and established at diagnosis and monitored throughout the follow-up [V, A].
- All side effects should be identified and treated if possible, namely physical and psychosocial [V, A].
- The development of an individual survivorship monitoring and care plan is recommended [V, B].
- Recommendations for a healthy life style should include smoking cessation, regular exercise, healthy diet and weight management [V, B].
- Clinical trials should address long-term cancer survivorship and should include patient related outcomes [V, B].
- Quality control of care should be established [V, B].
- Each visit should be composed of the following [V, A]:
  - Patient history (including identification of relevant symptoms and side effects)
  - Physical examination (including a speculum and bimanual pelvic examination)
  - Imaging and laboratory tests should be performed only based on risk of recurrence, symptoms or findings suggestive of recurrence and/or side effects.
  - Regular review of an ongoing survivorship plan that can be shared with other healthcare providers.
Original research

- Oncological follow-up
  - Patients should be educated about symptoms and signs of potential recurrence [V, A].
  - Appropriate imaging test (MRI, ultrasound for pelvic assessment, CT scan or PET-CT for systemic assessment) should be used in symptomatic women [IV, A].
  - In case of suspected tumor persistence, recurrence or second primary cancer, histological verification is strongly recommended [V, A].
  - Vaginal vault cytology is not recommended [IV, D].
  - After fertility sparing treatment, follow-up should include HPV testing (at 6–12 and 24 months) [V, A].
- Monitoring of quality of life and side effects
  - Quality of life and side effects should be regularly assessed at least by the physicians/clinical care nurses and if possible by patients (using patient related outcomes). Patient self-reporting of side effects should be encouraged during and after treatment with the same frequency as medical visits [IV, B].
  - A checklist of potential main side effects should be included in the patient survivorship monitoring and care plan (eg, sexual dysfunction, lymphedema, menopausal symptoms and osteoporosis, genito-urinary and gastrointestinal disorders, chronic pain, fatigue) [IV, A].
  - After CTRT and BT, patients should be counseled about sexual rehabilitation measures including the use of vaginal dilators. Topical estrogens are indicated [IV, B].
  - Hormone replacement therapy is indicated to cervical cancer survivors with premature menopause and should be consistent with standard menopausal recommendations [IV, B]. Physical and lifestyle changes may also help [V, C].
  - Bone status should be assessed regularly in patients with early menopause [V, B].

Follow-up After Definitive CTRT and BT
- Follow-up should be performed/coordinated by a physician experienced with follow-up care after radiotherapy and BT including monitoring of early, and late treatment-related side effects [V, A].
- The same imaging method used at the start of treatment should be used to assess tumor response [V, B].
- Routine biopsy to assess complete remission should not be performed [IV, D].
- Cytology is not recommended in detecting disease recurrence after radiotherapy [IV, D].
- Imaging (pelvic MRI±CT scan or PET-CT) should be performed not earlier than 3 months after the end of treatment [IV, B].
- In patients with uncertain complete remission at 3 months post-radiotherapy, the assessment should be repeated after an additional 2–3 months with biopsy if indicated [IV, B].

Quality of Life and Palliative Care

- Early palliative care, integrated with oncological treatments, should be offered by the clinical team to all the patients diagnosed with advanced cervical cancer for managing symptoms and improving quality of life. A multidisciplinary approach must be included in the care plan with discussion and planning for specific treatment of these symptoms [IV, A].

Pain
- Opioids are the main analgesics for the treatment of moderate to severe cancer-related pain; the first option is oral morphine [I, A]; but other opioids and alternative routes (transdermic, subcutaneous) can be required in specific situations (ie, intestinal obstruction, problems with swallowing, renal failure) [III, B].
- If opioids alone do not provide sufficient pain relief cancer-related neuropathic pain should be treated with a combination of opioids and carefully dosed adjuvants (gabapentin, pregabalin, duloxetine, and tricyclic antidepressants) [III, B].
- Severe pelvic cancer pain unresponsive to an opioid regimen can benefit from other procedures like plexus block or spinal analgesia techniques [III, B].
- Palliative EBRT (if feasible) is effective for painful pelvic progression and bone metastasis [IV, B].

Renal Failure
- Urinary derivation by ureteral stent or percutaneous nephrostomy should be considered to treat renal failure caused by tumoral obstruction. There are no clear guidelines to predict which patients will benefit from these procedures in terms of survival and quality of life, and its indication should be discussed carefully [IV, C].

Malignant Intestinal Obstruction
- Medical management of malignant intestinal obstruction consists of antisecretory, corticosteroids, and antiemetic drugs. A nasogastric tube is recommended if vomiting and discomfort persist in spite of medical management. Surgical procedures can be considered in selected patients [IV, B].

Vaginal Bleeding and Discharges
- In the case of vaginal bleeding, vaginal packing, interventional radiology (selective embolization) or palliative radiotherapy (if feasible) are recommended. There is not enough evidence to prefer one over the other. In the case of massive refractory bleeding, palliative sedation can be considered. Malodorous vaginal discharge can be improved with vaginal washing and the use of a vaginal metronidazole tablet [IV, B].

Psychosocial Suffering
- In patients with cervical advanced cancer, a multidisciplinary approach of physicians, nurses, psychologists, social workers, and community health workers is needed to manage psychosocial and spiritual suffering associated with social stigma deriving from genital disease, malodorous vaginal discharge, etc [IV, A].

Cervical Cancer in Pregnancy

- Every patient diagnosed with cervical cancer in pregnancy must be counseled by a multidisciplinary team. This team

Follow-up: After definitive CTRT and BT

- Follow-up should be performed/coordinated by a physician experienced with follow-up care after radiotherapy and BT, including monitoring of early and late treatment-related side effects [V, A].
- The same imaging method used at the start of treatment should be used to assess tumor response [V, B].
- Routine biopsy to assess complete remission should not be performed [IV, D].
- Cytology is not recommended in detecting disease recurrence after radiotherapy [IV, D].
- Imaging (pelvic MRI±CT scan or PET-CT) should be performed not earlier than 3 months after the end of treatment [IV, B].
- In patients with uncertain complete remission at 3 months post-radiotherapy, the assessment should be repeated after an additional 2–3 months with biopsy if indicated [IV, B].
Several treatment modalities are available and should be considered [V, A].

- Given the large spectrum of therapeutic options, the multidisciplinary team should recommend a treatment plan according to the patient's intention, tumor stage, and gestational age of pregnancy at the time of cancer diagnosis. The primary aims of the recommended treatment plan are the oncological safety of the pregnant woman as well as the fetal survival without additional morbidity [V, A].

- Treatment of patients with cervical cancer in pregnancy should be exclusively done in gynecological oncology centers associated with the highest level perinatal center with expertise in all aspects of oncologic therapy in pregnancy and intensive medical care of premature neonates [V, A].

**Clinical and Imaging Diagnosis**

- Clinical examination and histological verification of cervical cancer are mandatory [IV, A].

- Pathological confirmation may be obtained by colposcopy oriented biopsy or small cone (appropriate only during the first trimester of pregnancy, endocervical curettage is contraindicated) [IV, C].

- Preferred imaging modalities for clinical staging in patients with cervical cancer in pregnancy include pelvic MRI or expert ultrasound as part of the primary work-up. Gadolinium-based contrast agents should be avoided [III, A].

- The use of whole-body diffusion-weighted imaging MRI (WB-DWI/MRI) can reliably obviate the need for gadolinium contrast and radiation for nodal and distant staging during pregnancy. If not available, chest CT scan with abdominal shielding is an alternative. PET-CT should be avoided during pregnancy [IV, B].

**Oncological Management**

- Tumor involvement of suspicious nodes should be histologically confirmed because of its prognostic significance and the impact on the management up to 24 weeks of gestation (fetal viability) [IV, A].

- Minimally invasive approach could be considered before 14–16 weeks of gestation; however, the sentinel node biopsy concept using indocyanine green is still experimental [IV, C].

- Several treatment modalities are available and should be discussed with the patient taking into account the tumor stage, gestational week of pregnancy and the patient's preferences [IV, B]:
  - Delay of oncological treatment until fetal maturity (if possible >34 weeks of gestation) and initiate cancer-specific treatment immediately after delivery by cesarean section. This option might be considered if the term or fetal maturity is approaching.
  - Conization or simple trachelectomy in order to completely remove the tumor, obtain free margins and perform nodal staging if needed, with the intention to preserve the pregnancy.

  - Radical surgery or definitive CTRT according to the disease stage as recommended outside pregnancy, if the woman decides not to preserve the pregnancy. Pregnancy termination is recommended before any treatment after the first trimester, and fetus evacuation before CTRT, if possible.

  - Chemotherapy until term of pregnancy (37 weeks of gestation) and initiation of definitive cancer-specific treatment immediately after delivery by cesarean section. At least a 2 week interval between chemotherapy and surgery is recommended. In patients with locally advanced disease or residual tumor after surgical procedure that cannot be completely removed (risk of premature rupture of amniotic membranes and/or cervical insufficiency), chemotherapy based on cisplatin or carboplatin can be considered starting after 14 weeks of pregnancy. Combination with taxanes is an option. Bevacizumab and checkpoint inhibitors are contraindicated.

  - Before starting each cycle of chemotherapy, an assessment of treatment response should be made by clinical examination and transvaginal or transrectal ultrasound. If no response is achieved after 2 cycles of chemotherapy during pregnancy, treatment strategy should be re-evaluated.

**Pregnancy Management**

- Spontaneous delivery appears to have negative prognostic impact in patients with cervical cancer in pregnancy. Thus, cesarean section is the recommended mode of delivery [IV, B].

- At the time of cesarean section, definitive cancer specific treatment should be performed corresponding to that of non-pregnant women, taking into account the treatment that has already been given during pregnancy [IV, A].

**Rare Tumors**

- Histopathological diagnosis of rare cervical tumors needs confirmation (second opinion) by an expert pathologist [IV, A].

- Treatment and care of rare cervical tumors needs to be centralized at referral centers and discussed in a multidisciplinary tumor board [IV, A].

**ALGORITHMS**

**Management of T1a Disease**
Primary Treatment of T1b1, T1b2, and T2a1 Tumors

- LN positive
- LN negative
- Surgical therapy
- Definitive CRT + XRT
- SLA therapy
- Definitive CRT + XRT
- LN intraprostatic staging
- Not done or LN negative

RADICAL HYSTERECTOMY

Adjuvant Treatment of T1b1, T1b2, and T2a1 Tumors

- LN involvement (pN1+)
- Involvement of vaginal margins
- Parametrial involvement
- Combination of negative prognostic factors
- CRT
- Definitive CRT + XRT
- Radiotherapy
- Observation

Fertility Sparing Treatment - Selection of Candidates

- Desires of future fertility
- No
- Squamous cell carcinoma or HPV-associated adenocarcinoma
- No
- Radical LND staging
- Fertility sparing treatment cannot be considered
- Tumor ≥2 cm
- No
- Fertility sparing treatment cannot be considered

Suitable candidate for fertility sparing treatment

- Fertility sparing treatment cannot be considered a standard treatment

Fertility Sparing Treatment - Management

Invasive Cervical Cancer Diagnosed on a Simple Hysterectomy Specimen

- Definitive CRT + XRT
- Observation

Fertility Sparing Treatment - Selection of Candidates

- LN lymph node
- Public lymph node staging (sentinel lymph node) should always be the first step in each fertility sparing therapy procedures (except for T4A lymphovascular space involvement negative disease). All sentinel lymph nodes from both sides of the pelvis and any suspicious LN should be sent for frozen section. If sentinel lymph node cannot be detected on either pelvic side, a systematic pelvic lymphadenectomy should be performed on that side. Intraoperative assessment of LN status is highly recommended.
Management of Locally Advanced Disease

Cervical Cancer in Pregnancy

Cervical cancer in pregnancy?

 Desire to preserve pregnancy?

 Yes

 Complete tumor resection achievable by excision or simple tractolectomy

 Yes

 Pregnancy termination + standard radical surgery or definitive CTRT

 No

 Cervical or simple tractolectomy + concurrent LA staging

 No

 Fetal maturity approaching

 Yes

 Delay oncological treatment until fetal maturity (34-38 weeks)

 Chemotherapy until term of pregnancy (37-38 weeks)

 Cancer specific treatment after delivery

 No

 Cancer specific treatment after delivery

 CTRT: chemoradiotherapy, LA: local assessment

 Several treatment modalities are available and should be discussed with the patient taking into account the tumour stage, gestational week of pregnancy and patient’s preference. Standard treatment according to the disease stage as recommended outside pregnancy, if the woman decides not to preserve the pregnancy. Pregnancy termination is recommended before any treatment after the first trimester, and before evacuation before CTRT. The aim is to completely remove the tumour, obtain free margins and perform nodal staging if needed, with the intention to preserve the pregnancy. This option might be considered if the fetal maturity is approaching. Delay of oncological treatment until fetal maturity (if possible ≥34 weeks of gestation) and initiate cancer-specific treatment immediately after delivery by caesarean section. In patients with locally advanced disease or residual tumor after surgical procedure that cannot be completely removed (risk of peritoneal rupture of anostotic membranes and/or cervical insufficiency), chemotherapy based on cisplatin or carboplatin can be considered starting after ≥34 weeks of pregnancy. The decision to start a cycle of chemotherapy, as assessment of treatment response should be made by clinical examination and tomography. In case of advanced disease, it can be recommended after a cycle of chemotherapy during pregnancy, treatment strategy should be re-evaluated. At least a two-week interval between chemotherapy and surgery is recommended.

Recurrent Disease

Definitive CTRT and BT - General Aspects

Definitive management (ie, without tumor related surgery) consists of EBRT with concomitant platinum-based chemotherapy and BT. Delay of treatment and/or treatment interruptions have to be prevented to avoid tumor progression and accelerated repopulation. The overall treatment time including both EBRT and BT should therefore not exceed 7 weeks.

Definitive CTRT and BT

Target contouring for EBRT should be based on 3D imaging (preferably fused MRI and PET-CT) performed in the supine treatment position. Controlled bladder filling is recommended to minimize uterus movements and to push the intestines away. The result of the gynecological examination (ie, clinical drawing and description) as well as diagnostic imaging should be available during the contouring phase. A contouring protocol including a margin strategy for handling of internal movement (ITV) should be used to minimize irradiation of organs at risk. The EMBRACE II protocol may serve as a template. The tumor related target volume for EBRT (CTV-T) includes the primary cervical tumor (GTV-T), the uterus, parametria and upper vagina (or minimal 2 cm tumour-free margin below any vaginal infiltration respectively) and is optimally defined on MRI with assistance of the clinical findings.

The elective target (CTV-E) includes the obturator, internal, external and common iliac and presacral regions. The inguinal nodes should be included if the primary tumor involves the distal third of the vagina. A reduced elective target volume for EBRT without the common

PRINCIPLES OF RADIOTHERAPY

First line

Platinum based chemotherapy ± bevacizumab ± cetuximab

Pelic residual disease

Extrapelvic oligometastatic disease

ECOG ≥2

EOG ≥3

No

Radical pelvic radiotherapy

Additional regional treatment

Chemotherapy

Best supportive care

compliant

ECOG: Eastern Cooperative Oncology Group

The addition of bevacizumab to platinum-based chemotherapy is recommended when the risk of significant gastrointestinal/gyneco-cutaneous toxicity has been carefully assessed and discussed with the patient. The addition of pembrolizumab to platinum-based chemotherapy is recommended in patients with PD-L1 positive tumors, assessed as combined positive score >1 or >5; The patients with distant metastatic disease at diagnosis, who have responded to systemic chemotherapy, could be considered for additional radical pelvic radiotherapy (including image-guided brachytherapy in selected cases). Those with residual oligometastatic disease after systemic treatment could also be considered for additional regional treatment (surgery, thermal ablation, radiotherapy) in involved sites. Patients who progressed after first line platinum based chemotherapy should be offered anti PD-1 checkpoint if they had not previously received immunotherapy.
iliac nodes may be considered in low- and intermediate-risk T1b1 patients with negative LN and no LVSI. In case of PLN involvement indicating an increased risk of PALN spread (i.e., $>2$ pathological LN or involvement of common iliac region) and absence of surgical para-aortic staging, the elective target for EBRT should include the para-aortic region up to the renal vessels. In case of PALN involvement, the target volume includes at a minimum the region up to the renal vessels. Pathological macroscopic LN (GTV-N) are optimally localized with PET-CT and contoured on MRI.

The planning aim for EBRT is 45 Gy/25 fractions or 46 Gy/23 fractions using intensity-modulated radiotherapy/volumetric modulated arc therapy (IMRT/VMAT). A homogeneous dose from EBRT is needed in the central pelvis to ensure a safe platform for planning of BT. The use of an EBRT boost to the primary tumor and/or the parametria for complete or partial replacement of BT is not recommended.

Pathological macroscopic LN (GTV-N) should receive an EBRT boost. Simultaneous integrated boosting using coverage probability planning is recommended. Depending on nodal size and the expected dose contribution from BT a total dose of approximately 60 Gy EQD2 should be the aim of treatment. An alternative treatment option is surgical removal of enlarged nodes.

Image-guided radiotherapy with daily on-board 3D imaging is recommended for IMRT/VMAT to ensure safe dose application with limited PTV margins. Concomitant chemotherapy should be based on single-agent radiosensitizing chemotherapy, preferably cisplatin (weekly 40 mg/m²). If cisplatin is not applicable, alternative treatment options are weekly carboplatin (area under the curve (AUC) $=2$) or hyperthermia (if available). EBRT may also be applied without concomitant chemotherapy or hyperthermia according to patient selection (i.e., patients unfit for any chemotherapy).

Brachytherapy

IGABT is recommended, preferably using MRI with applicator in place. Repeated gynaecologic examination is mandatory, and alternative imaging modalities such as CT scan and ultrasound may be used. The tumour-related targets for BT include: 1) the residual gross tumor volume (GTV-Tres) after CTRT; 2) the adaptive high-risk clinical target volume (CTV-Tir) including the whole cervix and residual adjacent pathologic tissue; and 3) the intermediate-risk clinical target volume (CTV-Tir) taking the initial tumor extent into consideration. The BT applicator should consist of a uterine tandem and a vaginal component (ovoids/ring/mold/combined ring/ovoid). A combined intracavitary/interstitial implant is recommended in advanced cases to achieve the dose planning aim (see below), in particular in case of residual disease in the parametrium.

Ultrasound (transabdominal and/or transrectal) maybe used to intraoperatively support applicator insertion (avoidance of uterine perforation by the tandem, guidance of interstitial needles). In IGABT, the planning aim should be to deliver a BT dose of 40 to 45 Gy EQD2 to reach a total EBRT+BT dose of 85 to 95 Gy EQD2 (D90) (assuming 45 Gy through EBRT) to the CTV-Tir equal to or greater than 60 Gy (D98) to the CTV-Tres and equal to or greater than 90 Gy (D98) to the GTV-Tres. The use of three dimensional and 2D dose volume and point constraints for rectum, bladder, vagina, sigmoid, and bowel are recommended, and they have to be based on the published clinical evidence. Even though point A dose reporting and prescription have been surpassed by the volumetric approach, a point A dose standard plan should be used as a starting point for stepwise treatment plan optimization to retain the pear shaped iso-dose pattern with a high central dose. This is especially important for the combined intracavitary/interstitial technique to avoid overlapping of the interstitial needles.

BT should be delivered in several fractions as high dose rate (usually 3–4) with at least 6–8 hours interval or pulse dose rate delivered in one fraction (50–60 hourly pulses) or 2–3 fractions (15–24 hourly pulses) to respect the limitations of current radiobiological models for speed and capacity of radiation damage repair. In large tumors, BT should be delivered within 1 to 2 weeks toward the end of or after CTRT. In limited-size tumors, BT may start earlier during CTRT. For the tumour-related targets (GTV-Tres, CTV-Tir, CTV-Tres), the use of external beam therapy for giving an extra dose (e.g., parametrial boost, cervix boost) is not recommended, even when using advanced EBRT technology such as stereotactic radiotherapy or particle therapy. The use of a midline block for boosting the parametrum is not recommended when applying advanced image-guided radiotherapy and IGABT. Care should be taken to optimize patient comfort during (fractionated) BT. Preferably this includes a multidisciplinary approach. Intracavitary and combined intracavitary/interstitial BT implants should be performed under anesthesia.

Adjuvant Radiotherapy or CTRT

Adjuvant radiotherapy or CTRT follows analog principles for target contouring, dose and fractionation as outlined for definitive treatment. Different concomitant and/or sequential chemotherapy schedules have been established including cisplatin alone or combinations of cisplatin with other agents such as 5-FU or paclitaxel. Carboplatin should be considered for patients unfit for cisplatin. The application of IMRT/VMAT and image-guided radiotherapy is recommended as treatment-related morbidity is reduced. Additional BT as part of adjuvant radiotherapy or CTRT should be considered only if a well-defined limited area accessible through a BT technique is at high risk of local recurrence (e.g., positive resection margins in vagina or parametrium). Such adjuvant BT should follow the major principles outlined above for IGABT.

Definitive 3D Conformal EBRT or CTRT and Radiography-based BT

Three-dimensional conformal radiotherapy alone or as definitive concomitant CTRT (platinum based) ± para-aortic radiotherapy and/or 2D radiography based BT is recommended, if intensively modulated radiotherapy and/or IGABT are not available. In case of 3D conformal radiotherapy and/or radiography based BT, the recommendations for EBRT and IGABT as outlined above in regard to target, dose, fractionation, and overall treatment time have to be respected as much as possible. A sequential LN boost is applied as appropriate after completion of 3D EBRT. Planning aim for BT should be based on point A. Dose to point A should be equal to or greater than 75 Gy (EQD2) in limited width adaptive CTV-Tir (≤3 cm) and should aim at higher doses in large width adaptive CTV-Tir (>4 cm). In addition, dose for the maximum width of the adaptive CTV-Tir should be reported. Radiography...
based dose point constraints - plus 3D dose volume constraints as available - for rectum, bladder, vagina, sigmoid, and bowel are recommended, and must be based on published clinical evidence.

**PRINCIPLES OF PATHOLOGICAL EVALUATION**

**Requirements for Specimen Submitted for Pathological Evaluation**

Patient information, previous cervical cytology, histological specimens, clinical and radiological data, colposcopic findings and information on previous treatment (eg, surgery, radiotherapy) need to be included on the specimen request form. Details of cytology, biopsy, and surgical specimen (cone/loop specimen, trachelectomy, type of hysterectomy, presence of ovaries and fallopian tubes, presence of LN and designation of the LN sites, presence of vaginal cuff, and presence of parametria) need to be itemized in the specimen request form. Biopsies and surgical specimens should be sent to the pathology department in a container with liquid fixative (“clamping” of surgical specimens on a surface may be useful). If the local situation requires biobanking of fresh tissue, surgical specimens should be submitted fresh with minimum ischemia time. Cytology specimens should be sent to the pathology department preferentially as liquid-based cytology. Smear preparations are not recommended. The former is necessary when an HPV test is requested. Immunocytochemistry is possible on LBC but of not recommended. The former is necessary when an HPV test and placing of each slice of tissue in a single cassette should be performed in a standardized procedure. All the specimens should be measured in three dimensions according to the recent ESO/ESP recommendations. If the cone can be oriented properly, the anterior and the posterior half should be inked with separate colors. It should further be recorded if the specimen is complete or fragmented. If more than one piece of tissue is received, every piece should be measured in three dimensions. All specimens should be entirely submitted for microscopic examination. Inking of the surgical margins of cone/loop specimens is recommended. Dissection of cone/loop specimens should be performed in a standardized procedure. All the pieces submitted should be in consecutive numerical order. This is important because if tumor is present in more than one piece, it needs to be known whether these pieces are consecutive and, thus, a single tumor is present or whether the tumor is multifocal. It is recommended to place only one piece of tissue in each cassette. There are also techniques that allow embedding of more than one piece in a cassette if they are small enough. In cases that do not comprise intact cone/loops, serial radial sectioning and placing of each slice of tissue in a single cassette should be performed.

**Specimen Grossing and Sampling**

**Biopsy/Cone/Loop**

Small biopsy specimens should be enumerated. The cone/loop specimens should be measured in three dimensions according to the recent ESO/ESP recommendations. If the cone can be oriented properly, the anterior and the posterior half should be inked with separate colors. It should further be recorded if the specimen is complete or fragmented. If more than one piece of tissue is received, every piece should be measured in three dimensions. All specimens should be entirely submitted for microscopic examination. Inking of the surgical margins of cone/loop specimens is recommended. Dissection of cone/loop specimens should be performed in a standardized procedure. All the pieces submitted should be in consecutive numerical order. This is important because if tumor is present in more than one piece, it needs to be known whether these pieces are consecutive and, thus, a single tumor is present or whether the tumor is multifocal. It is recommended to place only one piece of tissue in each cassette. There are also techniques that allow embedding of more than one piece in a cassette if they are small enough. In cases that do not comprise intact cone/loops, serial radial sectioning and placing of each slice of tissue in a single cassette should be performed.

**Trachelectomy**

The upper (proximal) surgical margin of a trachelectomy specimen should be inked. The upper margin of a trachelectomy specimen should be sampled in its entirety in a way that allows to measure the distance of the tumor to the margin. The vaginal margin should also be inked and examined totally as radial sections if no tumor is seen grossly.

**Hysterectomy**

The description of the specimen (hysterectomy, trachelectomy, presence of ovaries and fallopian tubes, presence of LN and indication of the LN sites, presence of vaginal cuff and presence of parametria) should be recorded and checked for consistency with the description given in the specimen request form. The presence of any gross abnormality in any organ should be documented. The dimensions of the uterus for a hysterectomy specimen and the cervix for a trachelectomy specimen should be documented. The minimum and maximal length of the vaginal cuff should be documented. The size of the parametria should be documented in two dimensions (vertical and horizontal). Gross tumor involvement of the parametrium, vagina, uterine corpus, or other organs should be documented. The relationship of the cervical tumor to the vaginal and parametrial margins (and upper margin in case of a trachelectomy specimen) should be measured and appropriate sections taken to demonstrate this. Radial/circumferential and vaginal margins should be inked. The gross appearance of the cervix should be documented and any gross tumor mass measured. If visible, the site of a previous cone biopsy should be documented. Gross tumors should be measured in three dimensions, namely, the horizontal extent and the depth of invasion.

The tumor site within the cervix should be documented. The cervical tumor should be sampled to demonstrate the maximum depth of invasion, the relationship of the tumor with the surgical borders, and the extension to other organs. When the tumor is small (or with tumors that cannot be identified macroscopically), the cervix should be separated from the corpus, opened and processed as for a cone/loop specimen. In the case of a large tumor, the hysterectomy or trachelectomy specimen should be opened in the sagittal plane. At least one block per centimeter of the greatest tumor dimension should be taken for large tumors.

Additional blocks including the cervix adjacent to the tumor should be taken to identify precursor lesions. The whole cervix should be sampled in the case of a small tumor or where no macroscopic tumor is identified. The uterine corpus, vagina, and adnexa should be sampled according to standard protocols if not involved by tumor. If the uterine corpus and/or adnexa are grossly involved, additional blocks should be sampled. The entire vaginal margin should be blocked. The parametria should be submitted totally for histological examination to assess tumor invasion and surgical margins. The use of large sections is optional and provides good information on tumor size and marginal status.

**Lymph Nodes**

All the LN should be submitted for histological examination. If the LN are grossly involved, representative samples are sufficient. If
**Macroscopic description of specimen(s) (biopsy, loop/cone, trachelectomy, hysterectomy)** including specimen dimensions (three dimensions), number of tissue pieces for loop/cones, and maximum and minimum length of vaginal cuff and the parametria in two dimensions.

**Requirements for Pathology Report**

- Previous pertinent histological exams of the cervical lesion/cancer, even if diagnosed in another institution, should be revised and integrated in the final report (e.g., cone biopsy and hysterectomy specimen)
- Description of the specimen(s) submitted for histological evaluation.
- Macroscopic description of specimen(s) (biopsy, loop/cone, trachelectomy, hysterectomy) including specimen dimensions (three dimensions), number of tissue pieces for loop/cones, and maximum and minimum length of vaginal cuff and the parametria in two dimensions.

**Macroscopic tumor site(s), if the tumor is grossly visible, in trachelectomy and hysterectomy specimens.**

**Tumor dimensions should be based on a correlation of the gross and histological features and include the depth of invasion or thickness and the horizontal dimensions.** Multifocal carcinomas are separated by uninvolved cervical tissue, each should be described and measured separately, and the largest used for tumor staging. In some studies, a distance of more than 2 mm was arbitrarily used to define multifocality. Multifocal carcinomas should not be confused with the scenario in which tongues or buds of invasive carcinoma originate from more than one place in a single zone of transformed epithelium.

**Specimens from prior conization and subsequent conization, trachelectomy, or hysterectomy should be correlated for estimation of the tumor size. This is important since different specimens may have been reported at different institutions. It should also be recognized that simply adding the maximum tumor size in separate specimens may significantly overestimate the maximum tumor dimension.** Histological tumor type according to the most recent WHO classification (currently 5th edition, 2020, in its updated version).

**Histological tumor grade if required.** It needs to be stressed that currently grading remains of uncertain value for squamous cell carcinoma and most subtypes of adenocarcinoma. For adenocarcinoma, the growth pattern (Silva Classification) is recommended.

**The presence or absence of lymphatic vessel invasion (LVI),** which may be confirmed by immunohistochemistry. The quantification of the number of lymph vascular vessels involved by tumor cells is not mandatory but advisable for future prospective studies.

**The presence or absence of venous invasion (VI) and of perineural invasion (PnI).**

**Coexisting precursor lesions such as squamous intraepithelial lesion/cervical intraepithelial neoplasia, adenocarcinoma in situ, stratified mucin-producing intraepithelial lesion and other pathological changes of the cervix.**

**Measurements of tumor distance to all surgical margins (including minimum distance of uninvolved cervical stroma).**

**Margin status (invasive and peri-invasive diseases). Specify all the margin(s).**

**LN status including SLN status, the total number of nodes found, the number of positive LN, the size of the largest metastatic focus, and the presence of extra-nodal extension.** In the eighth UICC TNM edition isolated tumor cell deposits are no greater than 0.2 mm (200 µm) and should be reported as pN0 (i+). Micrometastasis (200 µm to 2 mm in diameter) are reported as pN1(mi).

**Pathologically confirmed (if required, including immunohistochemistry/HPV DNA) distant metastases.**

**Provisional pathological staging pretumor board/multidisciplinary team meeting (UICC TNM 9th edition; American Joint Committee on Cancer, 9th edition).**
Items to be Included in the Pathology Report of Carcinomas of the Cervix

<table>
<thead>
<tr>
<th>Clinical/Surgical</th>
<th>Macroscopic</th>
<th>Microscopic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Specimen(s) submitted</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Loop/s cones:</td>
<td>Tumor dimensions</td>
<td></td>
</tr>
<tr>
<td>► Number of tissue pieces</td>
<td>► Horizontal extent (two measurements)</td>
<td></td>
</tr>
<tr>
<td>► Transverse and anteroposterior diameters of ectocervix; Length</td>
<td>► Depth of invasion or thickness</td>
<td></td>
</tr>
<tr>
<td>► Trachelectomy or Radical Hysterectomy:</td>
<td>► Histological tumor type (LVI)</td>
<td></td>
</tr>
<tr>
<td>► Weight and size</td>
<td>► Coexisting pathological findings</td>
<td></td>
</tr>
<tr>
<td>► Length of the cervix</td>
<td>► Squamous intraepithelial lesion/cervical intraepithelial neoplasia (SIL/CIN).</td>
<td></td>
</tr>
<tr>
<td>► Vaginal cuff:</td>
<td>► Adenocarcinoma in situ (AIS).</td>
<td></td>
</tr>
<tr>
<td>Minimum and maximum length</td>
<td>► Stratified mucin-producing intraepithelial lesion (SMILE).</td>
<td></td>
</tr>
<tr>
<td>► Size of parametria (vertical and horizontal)</td>
<td>Tumor distance to all margins (proximal /distal)</td>
<td></td>
</tr>
<tr>
<td>► Tumor size in three dimensions</td>
<td>Margins status (invasive and preinvasive diseases). Specify the margins(s)</td>
<td></td>
</tr>
<tr>
<td>► Macroscopic tumor site(s)</td>
<td>LN status (SLN status, number involved /number retrieved, size of the largest metastatic focus, and presence of extra-nodal extension)</td>
<td></td>
</tr>
<tr>
<td>► LN: number and size</td>
<td>Pathologically confirmed distant metastases</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pathological staging (TNM category)</td>
<td></td>
</tr>
</tbody>
</table>

* Tumor dimension should be based on a correlation of the gross and histological features.

Ancillary Studies

All invasive carcinomas and adenocarcinoma in situ require an ancillary test to show the association with HPV. The most widely available and used technique is p16 immunohistochemistry (robust surrogate marker). Alternatively, HPV DNA or mRNA E6-E7 genes, can be detected by in situ hybridization or PCR-based techniques. HPV testing of cytological specimens requires liquid based cytology and uses mostly DNA-based or less frequently RNA-based molecular techniques. PD-L1 testing for the selection of immune checkpoint therapy is performed on tumor tissue, either biopsies or surgical specimens. PD-L1 expression seems to be frequently expressed in cervical carcinomas with special emphasis on locally advanced and HPV independent tumors. Standardized testing and evaluation including regular quality assessment is required to obtain a reliable patient selection for therapy. Prospective clinical trials will provide further information on the proper use of antibodies, assays and scoring systems. Further reading is available in Online Supplementary File 1

Author affiliations

1. Department of Obstetrics and Gynecology, Charles University, First Faculty of Medicine, Prague, Czech Republic
2. General University Hospital in Prague, Prague, Czech Republic
3. University Hospital Careggi, Firenze, Italy
4. Clinical Research Unit, Institut Bergonie, Bordeaux, France
5. Department of Palliative Medicine, University of Navarra, Pamplona, Spain
6. Service d’Oncologie Radiothérapie, Hôpital Universitaire Pitié Salpêtrière, Paris, France
7. Instituto Portugués de Oncologia de Lisboa Francisco Gentil EPE, Lisboa, Portugal
8. Universidade Nova de Lisboa, Lisboa, Portugal
9. Department of Internal Medicine, Medical University of Graz, Graz, Austria
10. François Baclesse Centre de Lutte Contre le Cancer, Caen, France
11. Asklepios Clinic Altona, Hamburg, Germany
12. Asklepios Comprehensive Tumor Center, Hamburg, Germany
13. Hospital Graz II, Graz, Austria
14. Johannes Kepler Universität Linz, Linz, Austria
15. Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
16. Catholic University of Sacred Heart, Rome, Italy
17. Homi Bhabha Cancer Hospital and Research Centre, Visakhapatnam, Andhra Pradesh, India
18. CHUV, Lausanne, Switzerland
19. Northern Gynaecological Oncology Centre, Gateshead, UK
20. Radiotherapy, Erasmus MC Cancer Centre, Rotterdam, The Netherlands
21. University Medical Center, Rotterdam, The Netherlands
22. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
23. Hospital Universitari Vall d’Hebron, Barcelona, Spain
24. European Institute of Oncology IRCCS, Milan, Italy
25. Department of Obstetrics and Gynecology, Lund University Hospital, Lund, Sweden
26. Skåne University Hospital Lund, Lund, Sweden
27. University Hospitals Strasbourg, Strasbourg, France
28. Medical Oncology, Clinica Universidad de Navarra, Pamplona, Spain
29. Department of Radiation Oncology, Medical University of Vienna, Wien, Austria
30. Gynecologic Oncology, Nairi Medical Center, Yerevan, Armenia
31. National Cancer Institute, Kiev, Ukraine
32. Medical Oncology, Graz, Graz, Austria
33. Gynecologic Oncology, La Paz University Hospital, Madrid, Spain
34. Aarhus University Hospital, Aarhus, Denmark

Presented at

These guidelines statements were jointly developed by European Society of Gynaecological Oncology (ESGO), European Society for Radiotherapy and Oncology (ESTRO) and the European Society of Pathology (ESP) and are published in the International Journal of Gynecological Cancer, Radiotherapy and Oncology and Virchows Archiv. The articles are identical except for minor stylistic and spelling differences in keeping with each journal’s style. Either citation can be used when citing this article.

Twitter Pedro Peccatori @fedrophd

Acknowledgements The authors thank ESGO, ESTRO, and ESP for their support. The authors also thank the 155 international reviewers (physicians and patient representatives, see Appendix 2) for their valuable comments and suggestions. The authors thank the ESGO office, especially Kamila Macku, Tereza Ciacikova, and Katerina Shiravova, provided invaluable logistical and administrative support throughout the process.


Contributors The development group (including all authors) is collectively responsible for the decision to submit for publication. DC (chair), JL (chair), MRR (chair) and FP (methodologist) wrote the first draft of the manuscript. All other contributors have actively given personal input, reviewed the manuscript, and have given final approval before submission. DC is responsible for the overall content as the guarantor.

Funding All costs relating to the development process were covered from ESGO and ESP funds. There was no external funding of the development process or manuscript production.

Competing interests CCh has reported advisory boards for GSK, MSD and EISAI; SFL has reported advisory boards for MSD, GSK, AstraZeneca and Novartis; DL has reported consultant honoraria from AstraZeneca, Clovis Oncology, GSK, MSD, Immunogen, Genmab, Amgen, Seagen and PharmaMar, advisory boards for AstraZeneca, Merck Serono, Seagen, Immunogen, Genmab, Oncoinvest, Corcept and Sutro, research institutional funding from Clovis Oncology, GSK, MSD and PharmaMar, research sponsored by AstraZeneca, Clovis Oncology, Genmab, GSK, Immunogen, Incyte, MSD, Roche, Seagen and Novartis, and speakers’ bureau activities for AstraZeneca, Clovis Oncology, GSK, MSD and PharmaMar; UM has reported advisory boards for AstraZeneca (Steering committee member for CALLA.
Original research

Study; RN has reported research grants from Elekta, Varian, Accuray, Dutch Research Council, and Dutch Cancer Society; AO has reported personal fees for advisory board membership from Agenus, AstraZeneca, Clovis Oncology, Concept Therapeutics, Deciphera Pharmaceuticals, Eisai, EMD Serono, F. Hoffmann-La Roche, Genmab/Seagen, GSK, ImmunoGen, Itheos, Merck Sharp & Dohme de Espana, SA, Mersana Therapeutics, Novocure, PharmaMar, PilMe Oncology, Roche, Sattucklabs, Sutro Biopharma and Tesaro, and personal fees for travel/ accommodation from AstraZeneca, PharmaMar and Roche; DQ has reported advisory boards for Mimark inc; MPS has reported research grants and personal fees for workshops from Elekta AB; DC, MRR, FP, CC, AF, DF, DJK, FJ, CK, PM, RN, FPec, JP, SR, AS, VS, KT, IZ and JCL have reported no conflicts of interest.

Patient consent for publication Not applicable.

Ethics approval Not applicable.

Provenance and peer review Not commissioned; internally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information.

Author note Initiated through the ESGO the decision to develop multidisciplinary guidelines was made jointly by the ESGO, ESTRO, and ESP. The ESGO provided administrative support. The ESGO, ESTRO and ESP are nonprofit knowledgeable societies. *These guidelines were developed by ESGO, ESTRO, and ESP. The ESGO provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

ORCID iDs
François Planchamp http://orcid.org/0000-0002-8709-0410
Cyrus Chargari http://orcid.org/0000-0003-0119-3695
Daniela Fischerová http://orcid.org/0000-0002-7224-3218
Ana Dakin http://orcid.org/0000-0002-3592-7194
Denis Querleu http://orcid.org/0000-0002-3984-4812
Sandra Rubie Bernabé http://orcid.org/0000-0001-7857-5363
Artem Stepanyan http://orcid.org/0000-0003-1961-0004
Ignacio Zapardiel http://orcid.org/0000-0002-9175-7767

REFERENCES
SUPPLEMENTAL DATA - SUMMARY OF EVIDENCE

General recommendations

Given the declining incidence of cervical cancer, centralization is increasingly becoming important to ensure high quality of the diagnostic work-up, treatment, follow-up and rehabilitation. The quality of treatment can be assessed according to the ESGO quality indicators for cervical cancer surgery and radiation therapy published in 2020 and 2023, respectively. European institutions that meet the standards for proper cervical cancer surgery and chemoradiotherapy apply or have already obtained ESGO recognition for cervical cancer surgery and/or radiotherapy build a referral network available on the ESGO website.

The quality indicators include not only a sufficient case load, the training and experience of the surgeon or radiation oncologist, the discussion of each case within a multidisciplinary team, but also the support of continuous recruitment of patients for clinical trials.

Clinical trials have a major impact on cancer care, research practices leading to reduced mortality and prolonged survival, better supportive care and improved understanding of cancer risk, prevention and screening. This research is also leading to the validation of many new cancer treatments such as molecularly targeted therapies and immunotherapies.

Staging

TNM classification & FIGO staging

The main purpose of cancer staging is to help clinicians predict the prognosis for a cancer patient, to guide treatment planning and follow-up, to evaluate and compare treatment results, to facilitate exchange of information between health professionals and to help in identifying clinical trials that may be appropriate for the patient. The new version 9 of the American Joint Committee on Cancer (9 AJCC TNM) cervical cancer staging aligns with the revised 2018 FIGO (the International Federation of Gynecology and Obstetrics) staging for cervical cancer (see Table 1). The most important changes between FIGO 2009 and 2018 are presented in table 2: 1) the incorporation from imaging and pathologic findings to identify TNM categories and FIGO stage, 2) update of histopathology to reflect human papillomavirus-associated and human papillomavirus-independent carcinomas (WHO 2020), 3) the elimination of horizontal dimension as a parameter for T1a (FIGO IA), 4) the addition of a subcategory T1b3 to T1b (T1b1 (IB1) ≤2 cm, T1b2 (IB2) >2≤4 cm, and T1b3 (IB3) >4 cm), 5) introduction of pelvic LN involvement as N1 (FIGO IIIC1), and para-aortic LN involvement as N2 (FIGO IIIC2). Micrometastases (>0.2 mm but ≤2 mm in greatest dimension) are included in Stage IIIC.

It is essential that all cancers must be confirmed by microscopic examination. The histopathologic types are classified as described in the WHO Classification of Female Genital Tumours. Note must be made of LVS, which does not alter the stage, but may affect the treatment plan. The HPV status of the cancer may be indirectly determined by p16 immunohistochemical overexpression, which is considered a good surrogate marker of HPV-associated tumours or by RNA in-situ hybridization. The margins of an excision specimen should be reported to be negative for disease for final staging. Identifying patients suitable for treatment with the immune checkpoint inhibitors (pembrolizumab, nivolumab), may rely on PD-L1 immunohistochemistry defined as CPS (combined positive score) ≥1.

The FIGO tumour stage is allocated after all imaging and pathology reports are available to generate all 3 categories (TNM) (see Table 1). Pathological findings supersede imaging and clinical findings. Multidisciplinary team discussion of disparate findings is recommended. When in doubt, the lower staging
should be assigned. For all morphological subtypes, the term “microinvasive carcinoma” should be avoided and instead the use of specific TNM and FIGO stages is recommended. Stage is not to be altered later, for example at recurrence. A structured checklist is recommended for preoperative imaging to determine staging and other prognostic parameters important for individual treatment. The checklist should include, for example, the largest size of the tumour and, if fertility preservation is desired, the distance from the upper edge of the tumour to the internal cervical os and the craniocaudal length of the cervix; the minimum thickness of the unaffected stroma; invasion of the parametrium; invasion of the vagina (with division of the vagina into upper two-thirds and lower one-third); hydronephrosis (related or unrelated to the extent of the tumour); pelvic side wall invasion into pelvis muscles, fascia, neurovascular structures and skeletal parts of the bony pelvis; bladder/rectal invasion (distinguish between wall and mucosa/lumen invasion); lymphadenopathy (pelvic and/or paraaortie, other areas); adnexal mass(es); other spread (peritoneal spread, visceral organ metastases, etc.); associated benign conditions; note the presence of anatomical variants; possible tumour-related complications (e.g. thromboembolism, etc.). It should be noted that the TNM classification more accurately reflects the disease prognosis than the FIGO stage. For example, patients with pelvic and/or paraaortic LN metastases are designated as having stage IIIC regardless of the primary tumour size or local pelvic spread. The group of FIGO stage IIIC patients is extremely heterogeneous with highly variable survival rates. FIGO staging should also be documented as both provide complementary information and have been correlated to some extent.

Prognostic factors

Early stage disease: lymph node involvement appears the most powerful prognostic factor influencing survival rate. The presence of a large tumour, deep stromal invasion (>2/3 of the wall), corpus uteri invasion, and LVSI are other independent factors decreasing survival rates. The nodal metastasis rate, paracervical invasion and 5-year cancer death rate are increased with a decrease in the thickness of the remaining intact cervical fibromuscular stroma. The minimum thickness of uninvolved stroma seems to be more useful and objective parameter than the depth of cancer invasion, however, the threshold value of the thickness of cervical fibromuscular stroma sufficient as a barrier against extrauterine spread is not known. Further studies regarding the tumour-free distance and the quadrant of the minimum thickness of the uninvolved cervical stroma should be emphasized. The prognosis of some rare tumours such as neuroendocrine carcinoma of the cervix is worse compared with cervical squamous cell carcinomas or adenocarcinomas. Non HPV-related adenocarcinomas or adenosquamous carcinomas have worse survival than squamous cell carcinomas. Grade has little direct influence on survival within any stage.

Locally advanced disease

1) Patient related factors (age, comorbidity, performance status): advancing age is an independent negative prognostic factor for mortality in women with cervical cancer, even after adjusting for race, stage at diagnosis, tumour histology, and treatment. Often this may be due comorbidities and poor performance status, but many times women over 70 are significantly less likely to receive standard of care treatment and much more likely to receive less aggressive (palliative) treatment or no treatment. Diabetes has been associated with poor survival in cervical cancer patients. Thrombocytosis and anemia before treatment and during treatment correlate with worse survival.

2) Factors related to the primary tumour (histologic subtype, tumour size, and degree of invasion into neighboring organs/structures): histological subtype, tumour size and the degree of invasion in the direction of vagina, uterine corpus, parametria (right/left), bladder and rectum as well as (uni- or bilateral) hydronephrosis are well known prognostic factors as also reflected in the FIGO/TNM staging systems. To objectively determine prognosis according to the degree of local tumour spread in all directions, comprehensively and systematically assessed using MRI and clinical examination a tumour score (TS) has been developed, that based on a simple summation of points obtained from the FIGO/TNM staging elements for local tumour spread (see Table 3), and has been shown to precisely...
predict local control, morbidity and survival following definitive chemoradiotherapy and brachytherapy\textsuperscript{28-30}. TS can be used both at diagnosis and during treatment to assess the prognostic impact of local tumour regression observed at brachytherapy, which often is administered after 4-5 weeks of external beam radiotherapy and concomitant chemotherapy.

3) Nodal factors (number, size, morphology and metabolism): The presence of micrometastasis appears to be associated with a negative impact on both the disease-free survival and overall survival and should be treated as macrometastasis\textsuperscript{31}. Number of positive LN predict prognosis within stage IIIC\textsuperscript{32}. Position of the nodes may also be important with deteriorating survival with increasing level of nodal involvement: IIIC\textsubscript{1} level 1 (small pelvis), IIIC\textsubscript{1} level 2 (common iliac) and IIIC\textsubscript{2} (para-aortic)\textsuperscript{33}.

4) Biomarkers and radiomics (PET-CT hypoxia tracers, DCE-MRI, Doppler imaging; HPV integration; immunomarkers): imaging biomarkers are linked to clinical phenotype, thus with a potential for improving risk stratification and treatment\textsuperscript{34}. To predict aggressive phenotype, unchanged, increased or new areas of FDG avidity from baseline signify persistent or progressive disease which is associated with poor survival\textsuperscript{35-37}. For prediction of hypoxia novel PET-CT tracers based on fluorine-labeled nitroimidazoles have been tested\textsuperscript{38}. Similarly, poorly perfused presumably hypoxic tumours showed low enhancement on dynamic contrast enhanced imaging (DCE-MRI), worse response to chemoradiotherapy, decreased locoregional control and reduced survival\textsuperscript{39,40}. Similarly, low tumour ADC value on diffusion-weighted imaging (DWI) is associated with increased tumour cellularity and predicts an aggressive phenotype\textsuperscript{34}. On ultrasound, low vascular indices predict poor treatment response in locally advance cervical cancer\textsuperscript{41}. In addition, a hypoxic gene expression classifier was identified\textsuperscript{42}.

The growing body of literature indicates the potential of radiomics toward the realization of precision medicine. Imaging features from various sequences (e.g., T2 weighted MRI, DWI-MRI, DCE-MRI) and modalities (e.g. MRI, PET-CT, CT, ultrasound) may be processed separately and then integrated together with clinical, histologic and genomic information toward enhanced discovery of non-invasive biomarkers of prognosis and treatment response.

HPV-associated cervical cancer has a more favorable prognosis than HPV-independent cervical cancer\textsuperscript{43,44}. Approximately 10% of cervical carcinomas are HPV-negative\textsuperscript{43,44}. In a study, patients who had HPV- negative tumours were older, had more advanced disease at diagnosis, and were more frequently diagnosed with non-squamous histology; moreover, they had a significantly worse disease-free survival (60 months vs 132 months) and overall survival (77 months vs 154 months) compared with women who had HPV-positive tumours\textsuperscript{43}. Immunomarkers, such as lymphopenia and elevated neutrophil-to-lymphocyte ratio and others have been correlated with worse prognosis in patients with cervical cancer\textsuperscript{45}.

5) Predictive factors for specific oncological treatment: with the emerging incorporation of biological therapeutics such as immunotherapy in the treatment of cervical cancer, there is growing need for the establishment of predictive assays for selection of patients to ensure optimal cost/benefit with PD-L1 expression in relation to response to pembrolizumab as an example\textsuperscript{46}. Around 35% of cervical squamous cell carcinoma (C-SCC) and 17% of adenocarcinomas expressed PD-L1\textsuperscript{47}. PD-L1 overexpression is related to poor overall survival in patients with cervical cancer and poor progression free-survival in Asian patients with cervical cancer\textsuperscript{48}. Mismatch Repair Deficiency Microsatellite Instability was found in 11% of cervical cancer\textsuperscript{49}. Different biomarkers have been studied to predict response to immune checkpoint inhibitors\textsuperscript{50}.
Local clinical and radiological diagnostic work-up

The role of pelvic examination is to assess the presence of tumour and perform a tumour biopsy. In addition, evaluation of vagina/vulva/anus is recommended to exclude low genital tract intraepithelial lesions. Clinical examination is insufficient to assess tumour size and rule out parametrial invasion and locally advanced disease. For local staging purposes, MRI or ultrasound performed by trained sonographer provide the highest diagnostic performance, therefore extensive clinical examination using general anesthesia should be omitted. CT is inferior to MRI to document local tumour extension, similarly the PET-CT has less predictive value than MRI in terms of detection of local spread because of limited spatial resolution. The implementation of MRI or ultrasound in preoperative workup makes the use of cystoscopy, proctoscopy or intravenous urography redundant. Both imaging modalities can detect the depth of tumour invasion into bladder or rectosigmoid. Biopsy guided by endoscopy might be only required to exclude secondary cancer.

Nodal/distant diagnostic work-up

The detection rate of imaging regarding LN and other distant spread depends on their prevalence regarding tumour stage and on size of metastasis. Imaging (ultrasound, MRI, CT or PET-CT) shows high specificity in detection of nodal metastases (>90%) but very low sensitivity in detection of micrometastases (<2 mm) and small volume metastases (<5 mm). In early stages, the micrometastases are often undetected on imaging and surgical LN assessment is the gold standard for the diagnosis of LN node metastasis(es). T1a1 tumour with no lymphovascular invasion is associated with extremely low incidence of LN metastases and, therefore, LN staging is not useful. In locally advanced cervical cancer, the incidence of extrapelvic disease at the time of initial management is ranging from 10% to 30%, particularly in PALN and/or chest or supraclavicular region. The heterogenous data concerning the diagnostic performance of conventional and functional techniques in nodal staging makes any conclusion regarding the routine diagnostic method unreliable. PET-CT can detect PALN metastases only in patient populations with high probability for metastases. Novel imaging techniques such as WB-DWI/MRI or PET/MRI enable a single examination in locally advanced cervical cancer but remain restricted by limited availability, the need for specialized technical equipment and limited evidence. WB-DWI/MRI can be an option in the staging of pregnant women with cervical cancer. FDG-PET/MRI integrates high-resolution multi-planar morphologic and functional information from MRI with the metabolic data from FDG-PET, which seem to be useful for differentiation between metastatic and benign LN and may reduce false findings. Recent data suggest that FDG-PET/MRI is equivalent to MRI and superior to FDG-PET-CT for local staging of primary tumour; FDG-PET/MRI is comparable to FDG-PET-CT for nodal staging.

Given the limitations of non-invasive techniques to accurately identify small paraortic lymph node (LN) metastasis, the potential role of surgical staging will be discussed in a separate chapter. Inconclusive findings of metastatic lesion should undergo biopsy to confirm or rule out metastatic disease. Tru-cut (core-cut) biopsy is the preferred option because it allows histological assessment of the tumour tissue, fine-needle aspiration biopsy should be avoided.
Supplemental material

For this purpose, craniocaudal cervical length, tumour-to-internal cervical os distance are also measured; measured, and this should be clearly stated in the pathology report together with the reasons why the thickness and not the depth of invasion is given. In such cases, the base of the epithelium. For T1a1,2 the horizontal dimension is no longer considered in defining the upper boundary of a T1a carcinoma be reported to be negative for disease to do the final pathological stage. If the margins of the cone biopsy are positive for invasive cancer, the patient is assigned to T1b1.

Exceptions are allowed, for example, for large exophytic tumours>2 cm in the largest dimension, which should be staged based on the largest dimension even if they are superficially invasive (≤5 mm). In some situations (e.g. in infiltrated tumours) it is not possible to measure the depth of invasion. In such cases, the tumour thickness may be measured, and this should be clearly stated in the pathology report together with the reasons why the thickness and not the depth of invasion is given. In such cases, the pathologist and clinician should correlate tumour thickness with depth of invasion for staging and management purposes.5 A new primary tumour size cutoff value of 2 cm enables to evaluate potential candidates for fertility-sparing treatment. For this purpose, craniocaudal cervical length, tumour-to-internal cervical os diameter are also measured; (p<0.001).

The pelvic wall is defined as the muscular, fascial, neurovascular structures, and skeletal portions of the bony pelvis. Bullous edema does not permit a case to be assigned to stage IIA; (shading notation of r (radiology) and p (pathology) to indicate the findings that are used to allocate the case to Stage IIC (e.g. rIIIp, pIIIC). The type of pathology technique used should also be documented. The suffix (f) is added to the N category when metastasis is identified by fine-needle aspiration or core biopsy. The suffix (sn) is added to the N category when metastasis is identified only by sentinel lymph node biopsy. When in doubt, the lower staging should be assigned.

Adding notation of r (radiology) and p (pathology) to indicate the findings that are used to allocate the case to Stage IIIC (e.g. IIICp, IIICr). The type of pathology technique used should also be documented. The suffix (f) is added to the N category when metastasis is identified by fine-needle aspiration or core biopsy. The suffix (sn) is added to the N category when metastasis is identified only by sentinel lymph node biopsy. When in doubt, the lower staging should be assigned; metastasis to inguinal, mediastinal, supraclavicular and other lymph node regions beyond abdomen, intraperitoneal disease, lung, liver, or bone, excludes metastasis to pelvic or para-aortic lymph nodes or vagina.

<table>
<thead>
<tr>
<th>TNM CATEGORYa</th>
<th>FIGO STAGEb</th>
<th>CRITERIA</th>
</tr>
</thead>
<tbody>
<tr>
<td>T (TUMOUR)c</td>
<td>T CRITERIA</td>
<td></td>
</tr>
<tr>
<td>TX</td>
<td>Primary tumour cannot be assessed</td>
<td></td>
</tr>
<tr>
<td>T0</td>
<td>No evidence of primary tumour</td>
<td></td>
</tr>
<tr>
<td>T1</td>
<td>Carcinoma is strictly confined to the cervix (extension to the corpus should be disregarded)</td>
<td></td>
</tr>
<tr>
<td>T1a</td>
<td>IA</td>
<td>Carcinoma with maximum depth ≤5 mm</td>
</tr>
<tr>
<td>T1a1</td>
<td>IA1</td>
<td>Measured tumour invasion ≤3 mm in depth</td>
</tr>
<tr>
<td>T1a2</td>
<td>IA2</td>
<td>Measured tumour invasion &gt;3 mm and ≤5 mm in depth</td>
</tr>
<tr>
<td>T1b</td>
<td>IB</td>
<td>Carcinoma with deepest invasion &gt;5 mm, limited to the cervix uteri with size measured by maximum tumour diameter.</td>
</tr>
<tr>
<td>T1b1c</td>
<td>IB1c</td>
<td>Carcinoma with &gt;5 mm depth of tumour invasion and ≤2 cm in greatest dimension.</td>
</tr>
<tr>
<td>T1b2</td>
<td>IB2</td>
<td>Carcinoma &gt;2 cm and ≤4 cm in greatest dimension.</td>
</tr>
<tr>
<td>T1b3</td>
<td>IB3</td>
<td>Carcinoma &gt;4 cm in greatest dimension.</td>
</tr>
<tr>
<td>T2</td>
<td>II</td>
<td>Carcinoma invades beyond the uterus but has not extended onto the lower one-third of the vagina or to the pelvic wall</td>
</tr>
<tr>
<td>T2a</td>
<td>IIA</td>
<td>Involvement limited to the upper two-thirds of the vagina without parametrical invasion</td>
</tr>
<tr>
<td>T2a1</td>
<td>IIA1</td>
<td>Carcinoma ≤6 cm in greatest dimension</td>
</tr>
<tr>
<td>T2a2</td>
<td>IIA2</td>
<td>Carcinoma &gt;6 cm in greatest dimension</td>
</tr>
<tr>
<td>T2b</td>
<td>IIB</td>
<td>With parametrical invasion but not up to the pelvic wall</td>
</tr>
<tr>
<td>T3</td>
<td>III</td>
<td>Carcinoma invades the lower third of the vagina and/or extends to the pelvic wall and/or causes hydronephrosis or non-functioning kidney</td>
</tr>
<tr>
<td>T3a</td>
<td>IIIA</td>
<td>Carcinoma invades the lower third of the vagina, with no extension to the pelvic wall.</td>
</tr>
<tr>
<td>T3b</td>
<td>IIIB</td>
<td>Extension to the pelvic wall and/or hydronephrosis or non-functioning kidney (unless known to be due to another cause).</td>
</tr>
<tr>
<td>T4</td>
<td>IVa</td>
<td>Carcinoma has involved (biopsy-proven) the mucosa of the bladder or rectum or has spread to adjacent organs.</td>
</tr>
<tr>
<td>T4a</td>
<td>IVa</td>
<td>Carcinoma has invaded the bladder or rectum directly from the cervix</td>
</tr>
<tr>
<td>T4b</td>
<td>IVb</td>
<td>Carcinoma has invaded the bladder or rectum via the parametrium.</td>
</tr>
</tbody>
</table>

N (NODE) CATEGORYa

| N0            | Regional lymph nodes cannot be assessed |
| N0(i+)        | Regional lymph node metastasis |
| N1            | Regional lymph node metastasis to pelvic lymph nodes only |
| N1a           | Regional lymph node metastasis (>0.2 mm but ≤2.0 in greatest dimension) to pelvic lymph nodes |
| N1a1          | Regional lymph node metastasis (>2 mm but ≤2.0 in greatest dimension) to pelvic lymph nodes |
| N1a2          | Regional lymph node metastasis (>2 mm but >2.0 in greatest dimension) to pelvic lymph nodes |
| N2            | Regional lymph node metastasis to para-aortic lymph nodes, with or without positive pelvic lymph nodes. |
| N2a           | Regional lymph node metastasis to para-aortic lymph nodes, with or without positive pelvic lymph nodes. |
| N2a1          | Regional lymph node metastasis (>0.2 mm but ≤2.0 in greatest dimension) to para-aortic lymph nodes, with or without positive pelvic lymph nodes. |
| N2a2          | Regional lymph node metastasis (>2 mm but >2.0 in greatest dimension) to para-aortic lymph nodes, with or without positive pelvic lymph nodes. |

M (METASTASIS) CATEGORY

| M0            | No distant metastasis |
| M1           | Distant metastasis (clinical category) |
| M1a           | Distant metastasis (pathologic category) |

Table 1 - Revised FIGO 2018 and TNM staging cervical cancer2,6

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s).
FIGO staging was based primarily on clinical findings, in addition to plain radiographs; including intravenous pyelography can be used for staging.

**FIGO 2009**

**Stage IA**
- The classification of IA stage depended on both the extent of horizontal spread and the depth of disease invasion.

**IA carcinoma with maximum depth of invasion ≤5 mm with a horizontal spread 7.0 mm or less.**

**Stage IB**
- The creation of new subcategory (IB3) enables more consistent contribution of tumour size to prognosis. In addition, tumour size cutoff value of 2 cm enables to evaluate potential candidates for fertility-sparing treatment.

**IB1 Clinically visible lesion ≤4.0 cm in greatest dimension.**

**IB2 Clinically visible lesion >4.0 cm in greatest dimension.**

**IB3 Invasive carcinoma >4 cm in greatest dimension.**

**Stage III**
- The tumour extends to the pelvic wall and/or involves lower third of the vagina and/or causes hydronephrosis or non-functioning kidney. The lymph node status is not incorporated in stage III.

**IIIA Tumour involves lower third of the vagina, with no extension to the pelvic wall.**

**IIIB Extension to the pelvic wall and/or hydronephrosis or non-functioning kidney.**

**IIIC Involvement of pelvic and/or PALN (including micrometastasis), irrespective of tumour size and extent**

- **IIIC1 Pelvic lymph node metastasis only.**
- **IIIC2 PALN metastasis.**

**FIGO 2018**

All imaging modalities such as ultrasound, CT, MRI or PET-CT and pathologic findings can be used to complement clinical evaluation in assessing both tumour size and extent. The method used to assign the stage should be recorded. Pathologic findings take precedence over clinical assessment and imaging findings in assigning the FIGO stage.

**Stage IA**
- The horizontal dimension of the lesion is no longer considered in defining the upper boundary of IA stage.

**IA Carcinoma with maximum depth of invasion ≤5 mm.**

**Stage IB**
- The creation of new subcategory (IB3) enables more consistent contribution of tumour size to prognosis. In addition, tumour size cutoff value of 2 cm enables to evaluate potential candidates for fertility-sparing treatment.

**IB1 Invasive carcinoma with >5 mm depth of stromal invasion and ≤2 cm in greatest dimension.**

**IB2 Invasive carcinoma >2 cm and ≤4 cm in greatest dimension.**

**IB3 Invasive carcinoma >4 cm in greatest dimension.**

**Stage III**
- The carcinoma involves the lower third of the vagina and/or extends to the pelvic wall and/or causes hydronephrosis or non-functioning kidney and/or involves pelvic and/or PALN.

**IIIA The carcinoma involves the lower third of the vagina, with no extension to the pelvic wall.**

**IIIB Extension to the pelvic wall and/or hydronephrosis or non-functioning kidney.**

**IIIC Involvement of pelvic and/or PALN (including micrometastasis), irrespective of tumour size and extent**

- **IIIC1 Pelvic lymph node metastasis only.**
- **IIIC2 PALN metastasis.**

### Table 2 - Key updates of the 2018 FIGO classification compared to the prior version

**Locations included in TS score**

1. Maximal tumour diameter at the cervix (mm)
2. Left parametrium: not involved, proximal, distal, pelvic wall
3. Right parametrium: not involved, proximal, distal, pelvic wall
4. Vagina: not involved, upper 1/3, middle 1/3, lower 1/3
5. Corpus uterus: not involved, lower 1/3, middle 1/3, upper 1/3
6. Bladder: not involved, bladder wall, bulbar edema, mucosa involvement
7. Uterus: Not involved, unilateral hydronephrosis, bilateral hydronephrosis
8. Rectum: Not involved, mesorectum, rectal wall, mucosa
Management of T1a disease

Series published since the 2018 ESGO/ESTRO/ESP guidelines have led to minor changes in the 2022 update. Sentinel node procedures are now preferred to systematic node dissections in patients for whom nodal staging is considered necessary. The 2022 update includes a new recommendation for SH for patients with T1a1 or T1a2 adenocarcinoma who have completed childbearing.

Diagnosis and management of T1a cervical cancer should be based on expert pathology of an intact histologic specimen (cone or excisional specimen). Loop or laser conization is preferable to cold knife conization in women desiring preservation of fertility. Fragmentation of the specimen and thermal artefacts should be avoided as they can obscure the extent of the tumour and margin status. The specimen should be oriented for the pathologist to determine the exact location of the tumour. The pathology report should specify depth of invasion, the status of the margins, and assessment of LVSI; the horizontal extent is optional since it is no longer included in TNM/FIGO staging system. The status of the margins is important because patients with positive margins after LEEP or cold knife conization have a higher frequency of residual disease in completion hysterectomy specimens than those with clear margins.

The recommendations for treatment of stage IA have been updated in that a sentinel node procedure (not a systematic dissection) is recommended for LN staging if nodal staging is to be done. LN staging is not indicated in T1a1 LVSI-negative patients but can be considered in T1a1 LVSI-positive patients (unchanged recommendation).

Management of T1b1, T1b2, and T2a1 tumours

Laparotomy is the standard surgical approach to parametrectomy

The first version of the ESGO-ESTRO-ESP guidelines had been published just before the LACC study presentation in 2018, so it recommended minimally invasive surgery (MIS) as the preferred approach for radical hysterectomy. This new version, based on new evidence, recommends laparotomy as the standard approach for all procedures which include radical parametrectomy. However, it leaves space for MIS for LN staging, thus allowing sentinel lymph node (SLN) biopsy to be performed by laparoscopy or robotic surgery, and if the frozen section result is negative, only then laparotomy is performed. The radical uterine procedure can therefore be done from a transverse incision. Moreover, the new guidelines even open up an option to perform radical hysterectomy by MIS in a very low-risk cohort of patients with small tumours after conization with free margins. A retrospective multicentre study did not find an increased risk associated with MIS approach in such a low-risk cohort, and a post hoc analysis of the LACC study has come to the similar conclusion in patients after fertility sparing treatment.

Sentinel lymph node biopsy strongly recommended in primary surgical management

The new guidelines unequivocally recommend performing SLN in all patients with early-stage disease as part of primary surgical management. It reflects the accumulating data on much higher detection rate of LN positivity thanks to pathologic ultrastaging of SLN. In the recent prospective Sentinel study, almost 60% of cases with micro or macrometastases in SLN were detected only by pathological ultrastaging.

Random pelvic lymph nodes not recommended for intraoperative assessment

Intraoperative pathological assessment of SLN allows the detection of only about half of the cases with N, but in this group it allows preventing the combination of two radical treatment modalities. Such algorithm was also used in the SENTIX prospective study, in which all SLN were intraoperatively processed by frozen section and radical hysterectomy was abandoned in case of metastatic involvement. In 8% of patients, uterine radical procedure was abandoned intraoperatively, and only 7% was referred to adjuvant radiotherapy after radical surgery due to N1 status from the final pathology. The updated
version of the guidelines keeps recommending the intraoperative assessment of all SLN and/or suspected pelvic LN. However, the recommendation to examine randomly selected pelvic lymph nodes if SLN were not detected, has been omitted, because no method is available to determine which pelvic LN should be selected and a larger number of pelvic LN cannot be assessed by frozen section.

**Systematic pelvic lymphadenectomy remained a standard procedure for lymph node staging**

Although a large number of retrospective and several prospective studies have demonstrated the high sensitivity of SLN ultrastaging for pelvic LN status, there is currently only one prospective study in which SLN biopsy was not followed by a systematic pelvic lymphadenectomy. Due to the lack of prospective evidence on the safety of avoidance of systematic procedure, pelvic lymphadenectomy remains recommended staging procedure after SLN biopsy in T1b/T2a disease. Only the results of the ongoing 3 prospective studies may change clinical practice in the future.

**Limitation of lymph node dissection to the anatomical level I if sentinel lymph node not detected**

In the early stages, the distant spread of the disease is almost exclusively via lymphatic channels, and anatomically it almost always preserves the sequence of first pelvic and only later para-aortic LN. This is also why the staging of pelvic LN in cervical cancer is such an important prognostic parameter. In the SENTIX study, which is currently the largest prospective study with SLN biopsy and ultrastaging, such an anatomical gradient was demonstrated even within the pelvic lymph nodes in the cohort of 355 patients.

Only in 2% of patients an isolated positive SLN was detected at the pelvic level II cranially to iliac bifurcation, i.e., in common iliac or presacral regions. Therefore, the updated guidelines recommend limiting the LN dissection to the pelvic level I, below the iliac vessel bifurcation, if SLN is negative on frozen section bilaterally in the pelvis.

**Precise criteria for selection of candidates for ovarian preservation and transposition**

In the updated guidelines, the conditions for ovarian preservation are specified more precisely. Currently, data on the safety of ovarian preservation are available only from retrospective studies, and mostly not as a risk of recurrence in the ovaries, but as microscopic ovarian metastatic involvement from salpingo-oophorectomy specimen. Based on limited evidence, ovarian preservation can only be considered in women with usual tumour types. If the ovaries are preserved, a salpingectomy should always be performed.

**Avoidance of radical surgery if lymph node involvement is detected intraoperatively**

In the updated guidelines, the recommendation to abandon further radical surgery, both pelvic lymphadenectomy and radical hysterectomy, if any LN involvement is detected intraoperatively is retained. This recommendation was rated as controversial in the ESGO survey conducted in 2021 (data not published). However, another supporting argument for such a management appeared since the original guidelines were published. An ABRAX international retrospective study was designed to tackle this controversy, including only cases in which LN involvement was detected intraoperatively. Not only the completion of radical hysterectomy did not improve survival in the whole cohort, but no signal towards survival benefit was found in any of the subgroups, regardless of the tumour size or tumour type.

**Preoperative brachytherapy**

A multimodal strategy combing preoperative uterovaginal brachytherapy and radical hysterectomy performed 6 to 8 weeks later has been proposed in a limited number of centres for patients with T1b1 and T1b2 tumours (LN negative), with a level of evidence mainly based on retrospective series. It aims at eradicating local risk factors and avoiding adjuvant radiotherapy in patients with intermediate risk factors. High rate of pathological complete response (>70%) and excellent outcome were reported,
as shown in a recent meta-analysis of 3 randomized controlled trials and 10 non-randomized studies. A high-quality randomized controlled study is however required to confirm the benefit of this strategy and for now the use of preoperative brachytherapy followed by surgery (type A) is an option only in teams experienced in this approach (unchanged recommendation).

**Fertility sparing treatment**

Many studies addressing the fertility sparing treatment, mainly retrospective series, have been published in the course of the past 5 years, confirming the validity of the original ESGO/ESTRO/ESP guidelines. Given the possible spectrum of fertility sparing treatment, patient’s counselling and treatment should only be done in centres, which can offer all kinds of fertility sparing treatment (sentinel and full pelvic lymphadenectomy, conization, simple trachelectomy, radical trachelectomy, fertility sparing treatment following NACT, comprehensive staging in patients with necessity to abandon fertility sparing treatment) and perform an adequate number of procedures annually. Indeed, there is a clear tendency towards less radical cervical surgery, but upcoming data are not uniform. The psychological aspects of fertility sparing treatment should gain more attention. Patients should be very extensively counselled about potentially more aggressive behavior of neuroendocrine carcinomas, HPV-independent adenocarcinomas and carcinomasarcomas, and high uncertainties with respect to fertility sparing treatment. The fertility sparing treatment of rhabdomyosarcoma has been addressed as part of the ESGO-ESTRO-SIOP guidelines for the multidisciplinary management of vaginal cancer.

Any pregnancy following fertility sparing surgical procedure is associated with increased risk of PROM, preterm delivery, longer neonatal intensive care stay and lower birth weight, at least for conization and highest for abdominal radical trachelectomy. Various preventive methods can be discussed with the patient (e.g. regular measurement of vaginal pH-value, laparoscopic placement of cerclage, bed-rest and abstain from sexual intercourse, sick note, vaginal progestogen application, screening and treatment of asymptomatic bacteriuria, screening for cervical incompetence and progressive cervical shortening by transvaginal ultrasonography, fetal fibronectin testing, screening (and treatment) for asymptomatic vaginal infection, total cervical closure according to Saling and cervical cerclage, etc.). Patients should be given full details related to the different techniques of radical trachelectomy. Different surgical approaches for radical trachelectomy have been described such as radical vaginal trachelectomy, abdominal radical trachelectomy, total laparoscopic radical trachelectomy and robotic-assisted laparoscopic radical trachelectomy. To date, no randomized trial comparing these approaches has been published. Differences in oncologic outcome, pregnancy rates as well as pre-term delivery rates have been reported. Total laparoscopic radical trachelectomy should be used with caution based on the results of LACC and IRTA trial. Besides promising oncologic results, abdominal radical trachelectomy is associated with lowest pregnancy rate. Most comprehensive data exist for radical vaginal trachelectomy (if performed in a highly specialized centre). Moreover, radical vaginal trachelectomy appears to have the best oncological and pregnancy outcome. Robotic-assisted laparoscopic radical trachelectomy potentially might be an alternative to radical vaginal trachelectomy, but more and longer follow-up data are needed. Additional removal of upper parauterine lymphovascular tissue, if detectable, has the potential to improve validity of sentinel concept, but further studies are needed. Permanent cerclage should be placed in all patients during simple or radical trachelectomy. However, best material for permanent cerclage is still undecided. Encapsulation of residual tumour with adequate vaginal cuff at initial step of the surgery and avoidance of uterine manipulator use seems to be advantageous. No imaging modality can exactly predict the extent of requested local resection in order to reach tumour free margins with adequate safety distance. Postoperative histologic proven tumour free resection is mandatory, but indispensable safety margins are still a matter of debate.

NACT followed by fertility-sparing surgery is a promising strategy that might allow fertility preservation in patients with tumours >2 cm while providing acceptable oncologic outcome. However,
the optimal number of chemotherapy cycles, chemotherapy regimen as well as extent of cervical resection following NACT, are yet to be defined. Another, also experimental, option for patients with tumours >2 cm is upfront abdominal radical trachelectomy. Given that published series are limited in size, there are data demonstrating that neo-adjuvant chemotherapy followed by radical vaginal or abdominal trachelectomy has similar oncological results as assisted reproductive technology alone, but induce better pregnancy rate. Therefore, first mentioned approach should be the preferred one and should be performed in reference centres with a prospective evaluation of patients.

No recommendation can be provided for earliest possible realization of childbearing following fertility sparing treatment. After finishing of wound healing pregnancy seems possible, also use of *in vitro* fertilisation techniques. Routine hysterectomy following fertility sparing treatment and finished family planning is not generally recommended because it does not seem to increase oncologic safety despite limited available data.

Secondary hysterectomy should only be considered in patients with persistent clinical symptoms such as dysmenorrhea, dyspareunia, vaginal discharge, irregular bleeding or repeated cervical stenosis. Repeated abnormal Pap test after fertility sparing treatment is frequently observed with lower clinical relevance. Patient's strong wish can be another reason for considering secondary hysterectomy.

**Invasive cervical cancer diagnosed on a SH specimen**

Pathological examination of a hysterectomy specimen occasionally reveals invasive cervical cancer. This may be observed in case of hysterectomy for benign condition of the uterine corpus, or prolapse, or for management of preinvasive cervical disease. This clinical situation raises specific management issues: SLN no longer applicable, frequent need of repeated therapeutic interventions, difficult planning of radiation therapy - with in addition presence of bowel in the middle of the pelvis and possible adhesions, risks associated with cut-through surgery. It is in most circumstances the result of improper or misinterpreted preoperative workup. The attention of general gynecologists must be drawn on the need to carefully rule out cervical cancer before any decision of SH. It is mandatory to investigate by imaging and/or endocervical biopsy any enlarged cervix, and not to overlook abnormal uterine bleeding in circumstances when the presence of metrorrhagia is not an unusual symptom, for example in case of uterine leiomyoma or genital prolapse, or intraepithelial cervical disease. In the latter case, care must be taken to make sure that the biopsies have been performed in the most abnormal area of the cervix. Cone biopsy should be considered in case of doubt.

The recommendations are derived from the ones applying to the general case, with the objective of avoiding any discrepancy compared to general recommendations. The rationale when elaborating the recommendations specific to postoperative finding is to adapt the management, taking into account the circumstance, in order to meet the same objectives. Workup including imaging, need of pathology review and tumour board, surgical staging of nodal disease when applicable, availability of both surgery and radiation therapy in most cases, and avoidance of combining both modalities if possible, are principles shared with the general case. Based on these principles, the algorithm of staging procedures (imaging with or without surgery), surgical management, or radiation therapy according to clinical and pathological stage should also be as consistent as possible with the general situation. In this specific situation, additional available decisional parameters are the pathological margin status and presence of residual tumour.

The recent literature has not added a lot to knowledge. The most informative recent publication on the outcome of management modalities is a paper derived from the SEER database. The authors found that postoperative radiation therapy appears effective, however possibly less than radical surgery. The choice between surgery and radiation should however take into account the technical difficulties of surgery, the risk of postoperative complication, and the risk to have to offer postoperative radiation therapy. Surgery performed in the absence of the uterus follows the same principles than radical
hysterectomy and consists in removing the vaginal cuff and adjacent paracervix. Planning of radiation must also be adapted to the absence of uterus and possible bowel adhesions.

Management of locally advanced cervical cancer (T1b3-T4a)

**CTRT and BT**

The worldwide clinical implementation of image guided EBRT and IGABT (MRI) has provided a major breakthrough in the treatment of locally advanced cervical cancer with a significantly improved loco-regional control and a reduced morbidity in all stages of locally advanced cervical cancer compared to previous benchmark studies.\(^{171,172}\)

**Combining EBRT and BT**

IGBT encompassing combined intracavitary/interstitial techniques is pivotal for obtaining local control and provides superior survival compared with patients where BT is replaced with a boost of EBRT.\(^{171,173-175}\) The optimal combination of EBRT and BT involves an initial 5 weeks of EBRT with concomitant cisplatin providing not only tumour regression but also a homogenous dose platform from which an adaptive boost to above 90 Gy is delivered to the remaining tumour and the cervix (high-risk clinical target volume) at the time of BT.\(^{172}\) The BT boost should be administered in the final weeks of an overall treatment time (EBRT + BT) of maximally 50 days.\(^{171}\) The optimal dose of EBRT has been shown to be whole pelvic 45 Gy in 25 fractions. Parametrial boost by EBRT should not be used as substantial dose heterogeneity from EBRT makes summation of doses from EBRT and BT unsafe and incurs unnecessary dose to nearby organs at risk.\(^{177}\) Pathological nodes should be boosted to about 60 Gy (EQD2) with a simultaneous integrated boost considering the expected dose contribution from EBRT.\(^{33,172,178-180}\)

**Persistent tumour following CTRT and BT**

Persistence of the primary tumour following definitive CTRT and BT may be difficult to diagnose on imaging even by use of MRI and PET-CT.\(^{181,182}\) Further, many patients with apparent persistent disease on imaging at 3 months after treatment achieves complete remission within 6-9 months of further follow-up without further treatment.\(^{175}\) Repetitive imaging and biopsies may therefore be needed to establish the diagnosis of true persistent local disease. Circulating cell-free HPV DNA in plasma is currently being investigated as a new tool for assessing treatment response and monitoring of the disease.\(^{183}\)

**NACT before definitive CTRT and BT**

NACT given before definitive CTRT and BT has so far failed to show any benefit.\(^{184,185}\) A major reason for these findings is likely the prolongation of the overall treatment time including the NACT, which may induce accelerated repopulation.

**Adjuvant chemotherapy following definitive CTRT and BT**

A randomized phase III study reported more than 10 years ago showed that the addition of two courses of adjuvant gemcitabine/cisplatin improved progression free survival.\(^{186}\) However, this study raised several questions and has not seen widespread implementation.\(^{187}\) Other randomized trials including the notable OUTBACK trial as well as a meta-analysis, have unfortunately been negative.\(^{188-190}\)

**Completion/adjuvant hysterectomy in the context of definitive CTRT and BT**

Completion of radical hysterectomy does not improve survival of patients with intraoperatively detected LN involvement which any way are referred for definitive CTRT and BT.\(^{192}\) Likewise, studies on adjuvant hysterectomy following primary radiotherapy and BT have been negative.\(^{191-195}\) In addition, substantial perioperative and postoperative late morbidity has been observed.\(^{192,194}\)
**NACT before surgery**

Randomized studies conducted before the advent of concomitant chemotherapy showed a survival benefit for NACT and surgery compared with definitive radiotherapy\(^ {196} \). However, 2 recent randomized trials employing CTRT did not show this benefit\(^ {197,198} \). A meta-analysis of the data from these two studies has even suggested a 32% higher risk of relapse with the neoadjuvant strategy\(^ {199} \). Irrespective of the types of chemotherapy used over the last 30 years, the proportion of patients remaining inoperable after NACT has been stable at 25-30%. The proportion of the patients being referred for postoperative adjuvant radiation or chemoradiotherapy following NACT and surgery and thus exposed to triple treatment has also been stable at 25-30%\(^ {196} \).

**Role of surgery in T1b3 and T2a2 (LN negative) tumours**

The management of patients with IB tumours and tumour size greater than 4 cm remains controversial. That is why a separate chapter was designated for this topic in the updated guidelines. Currently, there is no evidence demonstrating the superiority of either surgical treatment or primary chemoradiotherapy in this cohort of patients. Prospective studies mostly compared primary radiotherapy with chemoradiotherapy, and in an older Italian study, survival did not differ between the two types of management\(^ {200-202} \). Inevitably, all these patients meet the criteria for intermediate-risk group (LN negative but a combination of negative prognostic factors such as larger tumour size, LVSI and deep stromal invasion), just by combining the size of the tumour with the depth of invasion. Surgical treatment should therefore only be used if radical hysterectomy remains the only main treatment modality without adjuvant treatment. In recent years, several retrospective studies have shown no survival benefit of the adjuvant treatment after radical hysterectomy in patients with intermediate-risk tumours\(^ {203-206} \). According to the updated guidelines, surgery in these patients should be limited to highly specialized centres with experience with type C radical hysterectomy.

**Recurrent/metastatic disease**

The phase 3 trial, GOG#240 analyzed the addition of bevacizumab, anti-VEGF agent, to the standard of care at that stage, platinum-doublet chemotherapy\(^ {207} \). The introduction of the antiangiogenic agent bevacizumab has extended median overall survival from about 12 to 17 months, since becoming the standard of care for this population. The addition of bevacizumab to platinum-based chemotherapy led to an unprecedented improvement in median overall survival for those patients with recurrent/metastatic disease, however, a new specific adverse event linked to bevacizumab use appeared, fistula. At final analysis the overall incidence of fistula (Grade 2 and Grade 3) was 8.6% among patients treated with bevacizumab compared with 1.4% for those without. All patients who developed fistula had had prior radiotherapy. No fistulas resulted in surgical emergencies, sepsis, or death, and in addition to pelvic irradiation, other factors associated with fistula included pelvic disease, pre-existing hypertension, and current tobacco use\(^ {207} \).

MK-3475-826/KEYNOTE-826 is a phase III randomized, double-blind, placebo-controlled study, designed to assess the benefit of adding pembrolizumab to chemotherapy with or without bevacizumab, in persistent, recurrent, or metastatic cervical cancer patients, in the frontline setting\(^ {208} \). A total of 617 eligible patients were randomly assigned in a 1:1 ratio to receive pembrolizumab/placebo plus platinum-based chemotherapy for up to 6 cycles and bevacizumab at the investigators’ discretion. The dual primary endpoints were progression-free survival and overall survival, each tested sequentially in patients with a PD-L1 CPS ≥ 1, in the intention-to-treat population, and finally, in patients with a PD-L1 CPS ≥ 10. After a median follow-up of 22.0 months the overall survival at 24 months was 53.0% in the pembrolizumab group and 41.7% in the placebo group (HR 0.64; 95% CI, 0.50 - 0.81; p=0.001), 50.4% and 40.4% (HR 0.67; 95% CI, 0.54 - 0.84; p<0.001), and 54.4% and 44.6% (HR 0.61; 95% CI, 0.44 - 0.84; p=0.001), in the PD-L1 CPS ≥1, intention-to-treat, and PD-L1 CPS ≥10 populations, respectively. Regarding the protocol-specified subgroup analysis, the overall survival benefit provided by the addition of pembrolizumab was
generally consistent across all patient subgroups. However, PD-L1 CPS<1 subgroup did not seem to obtain survival benefit among the PD-L1-selected subpopulations. Despite that the trial met its primary endpoint in the intent to treat population, based on the aforementioned subgroup analysis; both FDA and EMA have recently approved the use of pembrolizumab added to platinum-based chemotherapy plus or minus bevacizumab only for those patients whose tumours are CPS ≥1.

The phase III trial EMPOWER-Cervical-1/GOG-3061/ENGOT-cx9 compared cemiplimab, an anti-PD-1 antibody, versus the investigator's choice of single-agent chemotherapy in patients with advanced cervical cancer who had progressed after first-line platinum-containing chemotherapy. It is important to underscore the patients were included regardless of PD-L1 expression status. The primary endpoint was overall survival which was analyzed hierarchically in patients with squamous cell carcinoma followed by the intention-to-treat population. The trial was stopped, after the second planned interim analysis, based on pre-specified criteria for efficacy in the squamous-cell carcinoma population that demonstrated significantly improved overall survival in patients receiving cemiplimab monotherapy. Per-protocol final survival analysis was performed after 363 overall survival events were observed in the squamous-cell carcinoma patients' cohort, at a median follow-up of 30 months. These outcomes were recently presented at the 2022 ESMO congress. In the squamous cell carcinoma population, median overall survival was significantly longer with cemiplimab than with chemotherapy (10.9 months versus 8.8 months; HR 0.69; 95% CI, 0.56 - 0.85; p=0.0023), as well as in the overall population (11.7 months versus 8.5 months; HR, 0.65; 95% CI, 0.54 - 0.79; p<0.001). Moreover, overall survival was evaluated according to the status of PD-L1 in an exploratory analysis. In the most recent update, of 608 randomized patients, only 371 (61%) had valid baseline PD-L1 samples (182 in the cemiplimab arm and 189 in the chemotherapy arm). In the PD-L1 tested population, cemiplimab increased overall survival versus chemotherapy in patients with both PD-L1 ≥1% (HR 0.61; 95%CI, 0.45 to 0.83) and PD-L1<1% (HR 0.65; 95%CI, 0.42 - 0.98), with 38% and 35% lower risk of death, respectively. Following the final overall survival results of this trial, on 13th October 2022, the European Committee for Medicinal Products for Human Use adopted a positive opinion for cemiplimab in the treatment of patients with recurrent or metastatic cervical cancer, regardless of PD-L1 status, and disease progression on or after platinum-based chemotherapy.

Chemotherapy is the standard treatment in stage IVB cervical cancer. However, given that many women have a significant pelvic disease burden. Due to this fact, several retrospective series have studied the role of pelvic radiation in addition to chemotherapy for primary treatment. The conclusion of all these series is that pelvic radiation in addition to chemotherapy gives a significant overall survival benefit.

Follow-up during and after treatment/long-term survivorship

Cancer survivors include those who start treatment, continue treatment, have completed treatment, or are in clinical remission. Their follow-up focuses on assessing the effect of treatment and detecting recurrence, preventing and screening for subsequent primary tumours (oncological follow-up), but also on preventing, diagnosing and treating common sequelae of cancer and cancer treatment (monitoring quality of life and side-effects). Follow-up should be performed and coordinated by a physician experienced in the treatment and follow-up of gynaecological cancer patients. Communication with all physicians involved in survivorship care, including primary care physicians (i.e., general practitioners), is essential.

It is recommended to provide survivors with a summary of information about their cancer history, including their treatment, side effects, and recommendations for follow-up, health promotion and prevention [in a survivorship care plan]. At the time of transition of follow-up from a specialized centre to the primary care physician (or gynaecologist) such a long-term survivorship care plan provides an opportunity to transmit important information to the patient and relevant health care providers about long-term follow-up and potential late effects of cancer treatment.
Oncological follow-up

There is no evidence on the most appropriate follow-up strategy to detect tumour recurrence and prospective studies focusing on new follow-up strategies are warranted. The risk of recurrence is individual and depends on prognostic factors, treatment modality and patient characteristics. Therefore, surveillance programmes for patients undergoing treatment and after treatment for cervical cancer should be individualized to take these aspects into account.

The starting point for follow-up should be a treatment evaluation with documentation of tumour response. Recommended imaging after chemoradiotherapy is pelvic MRI, including DWI (diffusion-weighted imaging) (local extent) and CT or PET-CT (extrapelvic spread)\(^5\). The implementation of PET/MRI is still limited due to low availability, high costs and the need for specialized technical expertise.

Typically, more than three-fourths of recurrences occur within 2-3 years after primary treatment, follow-up should be more intensive during this period\(^213,214\). The most frequent recurrence sites are the pelvis (vaginal vault, cervix, parametrium, and pelvic wall) and the paraaortic LN. Patients without relapse rarely need to be followed in a specialized centre for more than 5 years after primary treatment. Counseling patients about the signs of recurrence remains an important part of survivorship care. Follow-up visits should include, at a minimum, a complete physical examination, including pelvic examination, and a patient history. Vaginal vault cytology has a low positive predictive value for detecting recurrence after chemoradiotherapy and surgery and is therefore not routinely recommended\(^213,215\). Instead of vaginal cytology, HPV testing may be useful in identifying vaginal precancer lesions or recurrence, but robust evidence is still lacking\(^215\). Imaging and laboratory tests, including serum biomarkers, are not routinely recommended because there is no convincing evidence that earlier detection of recurrence is associated with improved survival in recurrent cervical cancer.

Intensified oncological follow-up after treatment should focus on a group of patients with potentially recurrent disease that can be treated with curative intent or whose treatment will lead to long-term survival (i.e., those with early diagnosis of locoregional recurrence). This group should be offered more intensive follow-up with imaging and biomarkers. In order to facilitate more effective follow-up, different prognostic models have been developed to calculate the individual risk of recurrence and to design an optimal follow-up strategy\(^216\). For patients with early-stage cervical cancer after surgical treatment including fertility sparing treatment, simple and radical hysterectomy, the Annual Recurrence Risk Model (ARRM) with on-line risk calculation was proposed to tailor the follow-up strategy\(^217\). The ARRM model allows to assess the risk of recurrence in each year after surgery for 5 prognostically different cohorts, but also the potential site of recurrence (pelvic vs distant site). The ARRM model consists of five prognostic variables from initial tumour diagnosis (i.e., maximal pathologic tumour diameter, tumour histotype, grade, number of positive pelvic LN and presence of LVSJ) and helps stratifying patient follow-up per their risk profile. The model enables to differentiate between the lowest risk group with excellent prognosis where no regular follow-up is needed and highest risk group which will likely not benefit from any follow-up owing to prevailing distant metastases and expectedly very poor prognosis. The group with intermediate (26-50 points) and high-intermediate risks (51-75 points) has a risk of pelvic recurrence 5.2% and 13.7% for the first year of follow-up which steadily decreased by year three 3.2% for intermediate and by year five 3.9% for high-intermediate risk group. Both groups will benefit from tailored follow-up directed to pelvis using pelvic MRI or ultrasound 6 months after surgery and yearly for 3 to 5 years. The limitation of the model is that it is restricted to a group of early-stage disease treated by primary surgery and has not yet been prospectively externally validated. Similarly, prognostic factors were used to develop nomograms for 2-year progression-free survival, 5-year overall survival, and pelvic recurrence for locally advanced cervical cancer clinically limited to the pelvis treated with concurrent cisplatin-based chemotherapy and radiotherapy\(^216\).

Cervical cancer survivors have an increased risk of developing a second malignancy compared to the general population\(^218\). This is particularly pronounced for cancer caused by smoking- and radiation, where
the risk remained significantly elevated after ten years of follow-up. Radiation-induced second cancers, especially at radiated sites near the cervix include for example sigmoid colon, rectum/anus, urinary bladder. Counseling cervical cancer survivors about the risk of a second malignancies and active measures against smoking may become an important part of follow-up. Cancer survivors should participate in standard breast, colorectal, melanoma, lung screening programs according to national guidelines.

In case of suspected tumour persistence, recurrence or a second primary cancer, it is mandatory to confirm the finding by histological examination, if possible. For pelvic lesions, such as deeply located lesions in the endocervix (in case of conservative treatment or after definitive chemoradiotherapy), new lesions in the uterine cavity, involvement of parametrium or lymphnodes and others, ultrasound-guided tru-cut biopsy is the preferred method. In case of clinically or radiologically suspicious disease, a negative biopsy may not be conclusive. In case of inconclusive findings, repeat ultrasound-guided tru-cut biopsy with multiple cores taken from viable tissue (visualized on Doppler) is recommended. For any disease outside the pelvis, ultrasound-guided or CT-guided methods can be used to achieve pathological confirmation.

After follow-up at a specialized centre, when patients are referred back to their gynaecologist, long-term gynaecological follow-up is recommended as in the general population (annual population screening with physical and pelvic examination). A survivorship care plan consisting of a treatment summary, follow-up recommendations, and expedited referral procedures for suspected recurrence is suggested for a smooth transition from specialized cancer care to primary care.

**Quality of life and side-effects follow-up**

*General considerations:* in addition to follow-up for cancer recurrence, side effects of cancer and its treatment should be carefully prevented, detected, and monitored from the time of diagnosis, during and after treatment over the longterm. Acute (immediate or short-term) side effect develops right after exposure. Persistent (long-term) side effects arise during treatment and may persist over time (months to years after treatment is completed). Late side effects (latent) first appear months to years after the end of treatment. There is no standard definition of the transition time between acute and persistent side effects, but immediate side effects usually subside within the first few months after treatment. Some late side effects of radiotherapy may occur more than 2-3 years after the end of treatment, justifying the need for long-term follow-up.

Cervical cancer treatment can cause immediate common side effects such as a tight and shorter vagina, pain during intercourse and menopausal symptoms. Side effects vary depending on the type of treatments. After cervical cancer surgery, patients may experience pain, difficulty urinating (retention symptoms) and defecating, and may gradually develop lymphedema. Patients treated with radiotherapy reported that bowel cramps, diarrhea and bladder irritation during treatments intensified in the first 3 weeks with a plateau at the 5th week of treatment. Skin irritation, nausea, fatigue may also occur. If treatment includes platinum-based chemotherapy, patients often report peripheral neuropathy at the end of treatment. Regardless of treatment, patients suffer from poor quality of life (particularly in physical, social domains and well-being) and psychological distress.

Preventive supportive dietary measures, and care treatments such as loperamide, antispasmodic drugs, hydration counselling, should be considered when appropriate during radiation. Prevention of vaginal stenosis can start within one month after irradiation when acute mucositis reaction is resolving and it is carried out on a long-term basis. The screening (follicle-stimulating hormone, luteinizing hormone, and estradiol) and treatment for premature ovarian failure is recommended if the treatment might impair gonadal hormone function.

Although quality of life and psychological distress improve within a year after treatment, patients often report persistent treatment-related side effects, including but not limited to menopausal symptoms,
altered body image, sexual/vaginal dysfunction, diarrhea, lymphedema, peripheral neuropathy, fatigue, and social difficulties\textsuperscript{220,222}. Lower urinary tract and less commonly bowel dysfunctions, and sexual health problems are some common persistent or long-term toxicities associated with surgery. While fibrosis-related symptoms are mainly reported after radiotherapy (bladder urgency, diarrhea, vaginal stenosis). Retrospective evidence shows no significant differences in oncological outcomes and overall rates of side effects between patients treated with radical hysterectomy and postoperative chemoradiotherapy for LN metastasis compared with the definitive chemoradiotherapy group\textsuperscript{223}. However, both strategies are associated with different types of adverse events. Lower extremity lymphedema was more commonly reported after combined treatment with radical surgery and postoperative radiotherapy, whereas bladder or bowel problems and sexual dysfunction were more commonly reported after primary chemoradiotherapy. Lymphedema is one of the most frequent long-term side effects of surgery and/or radiation to the nodal group. Preventive recommendations include maintenance a normal body weight/avoiding weight gain in patients and a supervised exercise regimen. Compression (compressing arments or bandages) and physiotherapy should also be suggested. Treatment of lymphedema should be performed by a certified lymphedema specialist. Persistent fatigue is frequently reported after radiation and is associated with pre-existing comorbidities, severe pain, radiation doses, and other late persistent organ-related morbidities\textsuperscript{224}. Providers should inform and educate on sexual and vaginal health because vaginal stenosis and vulvovaginal dryness may occur. Vaginal dilation should be initiated early and performed indefinitely, with concurrent vaginal lubricants and topical estrogen recommended. If the ovarian function is not preserved (e.g. ovaries are not transposed from the field of radiation), premenopausal patients are particularly at risk of developing early menopausal symptoms, including osteoporosis with higher risk of bone loss and insufficiency fractures\textsuperscript{225}. Bone density status should be evaluated after treatment and should be monitored long-term. Dual-energy x-ray absorptiometry (DEXA, or DXA scan) is recommended immediately after treatment. Prevention (calcium supplementation if dietary calcium intake is insufficient to reach 1300 mg/day and vitamin D, weight-bearing exercise, healthy diet and smoking cessation). Treatment of osteoporosis should be the same as in the general population. Osteoporosis is treated with bisphosphonates or denosumab and vitamin D. Hormonal treatment can be considered to relieve menopausal (vasomotor) symptoms and to prevent menopause-related health risks, including osteoporosis. There is no evidence to contraindicate the use of systemic or topical menopausal hormone therapy in women with cervical cancer, as these tumours are not hormone dependent. The relative contraindications for menopausal hormone therapy in cancer survivors reflect those for the general population, including caution in survivors with coronary heart disease or hypertension, in those with increased genetic risk for cancers, and in current smokers, especially if over 35 years. Combination treatment with estrogen and progestin (for survivors with an intact uterus) or estrogens alone (for survivors without a uterus) should be initiated and continued until the average age of natural menopause (50 to 51 years)\textsuperscript{226}. Extended use of menopausal hormone therapy may be considered on a case-by-case basis. In addition to systemic hormonal therapies, local (vaginal) estrogen therapy (rings, suppositories, creams) may be considered to manage genitourinary symptoms of menopause, including vulvovaginal dryness and dyspareunia, as well as urinary symptoms of urgency, dysuria, or recurrent urinary tract infection\textsuperscript{227}. Recently, tissues elective estrogen complexes (TSECs) conjugated estrogens/bazedoxifene has been approved by the FDA for the treatment of menopausal symptoms in postmenopausal women\textsuperscript{228}. Lifestyle interventions are effective in improving fatigue, some physical functions and leading to weight loss in survivors. Psycho-educational programs could improovel mental health (mood disorders) and sexuality difficulties\textsuperscript{229-231}. Programs of physical activity have been developed for various cancers and have shown health benefit, mitigating side effects and improving quality of life, but have not been developed for cervical cancer patients\textsuperscript{232,233}.

If a late side effect occurs months or years after cancer treatment, a recurrence or a second primary tumour should be carefully ruled out. The type and treatment of a late side effect is no different from the treatment of a long-term side effect. Referral to specialized care long-term side effects clinics is encouraged.
How to follow-up:

- **Patient-reported outcomes (PROs):** evidence suggests that measuring PROs is important to complement physician-reported adverse events and to improve the accuracy of capturing symptomatic adverse events, such as those related to frequency, severity, and disruption of daily activities. Several randomized clinical trials have shown that routine self-reporting of treatment-related adverse events improves tolerability and quality of life, reduces the number of emergencies, and improves survival. However, this approach has not yet been developed for patients with cervical cancer. There are no gold standard PRO tools for monitoring of patients with cervical cancer. Quality of life questionnaires designed for cervical cancer (FACT-CX or the EORTC-CX) can be used. However, although these tools include different dimensions of quality of life, they do not perfectly capture the side effects of the treatments. Patient self-reported side effects questionnaires, including frequency, grading (degree of side effects), and interference with daily life (e.g., NCI PRO CTC AE or the EORTC library) could be designed to better capture patient unique treatment experiences. There is no standard for how and how often to monitor for side effects in cervical cancers, however, general oncology guidelines recommend early identification of side effects and supportive care needs with periodic reassessment during follow-up. The development of digital support tools is an opportunity to incorporate side effects monitoring into routine.

- **Checklist of long-term concerns:** to help physicians better monitor the side effects of treatment, the Gynecologic Cancer Intergroup - Symptom benefit committee has established a minimum checklist of key long-term concerns for gynecologic cancer survivors, including prevention, diagnosis, and treatment of long-term treatment-induced side effects (i.e., lymphedema, neuropathy, urinary/digestive disorders, fatigue, chronic pain, osteoporosis, sexual and hormonal disorders, cognitive problems); other health concerns, particularly sleep disorders, emotional difficulties and social difficulties; secondary and tertiary prevention with a particular focus on cardiovascular disease with lifestyle counselling.

### Quality of life and palliative care

Early palliative care should be integrated with oncological treatments and offered to all patients diagnosed with advanced cervical cancer in order to manage symptoms and improve quality of life. A multidisciplinary approach should be incorporated into the care plan with the aim of providing specific treatment for symptoms. Common clinical situations requiring palliation in advanced cervical cancer include pain, lymphedema, malignant intestinal obstruction, vaginal bleeding, malodorous vaginal discharge, renal failure, fistulas, cachexia, fatigue, and psychosocial suffering. Early palliative care is essential in providing, not only symptom control, but comprehensive, holistic care to those faced with advanced cervical cancer.

#### Pain in cervical cancer

Severe pelvic pain is common in advanced cervical cancer. Pelvic invasion often induces nerve compression or infiltration with neuropathic pain as a result (which is the most difficult to control). Apart from direct cancer injury, chemotherapy, radiotherapy, and surgery can also induce nerve damage. A variety of strong opioids are available for moderate to severe cancer-related pain and there is no superiority of one over another; however, the opioid of first choice for moderate to severe cancer pain is oral morphine. Extended-release presentations, other opioids, or alternative routes (transdermic, subcutaneous) can be required in specific situations (i.e. intestinal obstruction, problems with swallowing, renal failure, toxicity). When there is a neuropathic pain component, opioids alone may not provide sufficient pain relief; in this case, the use of adequate doses of analgesic adjuvants is useful. Gabapentin, pregabalin, duloxetine and tricyclic antidepressants are strongly recommended as adjuvants and also as single agents for first-line treatment of neuropathic pain.
Severe pelvic cancer pain unresponsive to an opioid regimen can benefit from other procedures like plexus block or spinal analgesia techniques\textsuperscript{242}. Spinal analgesia techniques are expensive, with risk of permanent neurological injury, and require specialized equipment and well-trained staff members. These techniques can be considered for patients at the end of life when other methods are no longer useful, according to clinical condition and patient’s preferences\textsuperscript{239}.

Palliative EBRT can be effective for painful pelvic progression (if no previous pelvic irradiation) and bone metastasis. In this situation of advanced non curable disease, hypofractionated palliative irradiation regimens are encouraged for to relief pain. Indication of palliative irradiation should take in count patient’s prognosis, symptoms, performance status, ability to attend the hospital for treatment, etc\textsuperscript{239,243,244}.

The malignant psoas syndrome is a rare and challenging cancer pain state with a symptomatic continuum of deep somatic nociceptive (muscle inflammation and spasm) and peripheral neuropathic pain (lumbar plexus injury). It is often refractory to standard multi-modal analgesic therapy and thus, eventually, needs advanced strategies for pain relief\textsuperscript{245}.

**Lymphedema**

Malignant lymphedema of the lower limb significantly reduces the quality of life of patients by changing body image, causing pain, immobility, and fluid secretion. It is also associated with an increased risk of recurrent local infections (e.g., cellulitis, erysipelas). In the context of cervical cancer, lymphedema of the lower extremities often has multiple causes including surgical interventions (e.g., lymphadenectomy), irradiation, or tumour compression of lymphatic vessels\textsuperscript{246}.

The evolution of treatments induced lymphedema is often chronic and generally cannot be cured. Surgical intervention is not indicated. The basic therapy consists of skin care, skin sanitation if needed, manual lymphatic drainage and compression therapy which in many cases should be realized by specialist professionals. In the case of spontaneous lymph fluid discharge targeted percutaneous lymphatic drainage can be effective\textsuperscript{247}.

**Malignant intestinal obstruction**

The development of a malignant intestinal obstruction is common in patients with gynaecological pelvic cancers and is associated with symptoms like pain, nausea, vomiting, constipation, or paroxysmal diarrhea. Treatment should primarily be symptom oriented. Medication must be given via parenteral routes. The medical management of malignant intestinal obstruction consists of antisecretory, anti-inflammatory, antiemetic, pain relief and promoting emptying strategies and drugs\textsuperscript{248}.

Nausea and vomiting can be controlled by antiemetics (e.g., metoclopramide), antipsychotics (e.g., olanzapine), corticosteroids (e.g., dexamethasone) or gastric protectors (e.g., ranitidine). The temporary placement of a nasogastric tube can be considered when the patient is experiencing discomfort (for example, continuous vomiting). On the other hand, gastrointestinal secretion inhibitors such as anticholinergics (e.g., butyl-scopolamine or octreotide; of the two, octreotide has shown itself to be superior to butyl-scopolamine) must be considered\textsuperscript{249}.

Although malignant intestinal obstruction is associated with a poor prognosis, surgical interventions may be indicated in certain patients with good performance status and stable disease. Individualization of the decision made by a multidisciplinary team is extremely important; some parameters have been found to be related to a bad prognosis for the use of a surgical approach: ECOG, high serum urea and low albumin levels\textsuperscript{250}.

Parenteral nutrition can be discussed for patients with good performance status and when it is expected that the obstruction can be solved. Otherwise, it would not make sense since it does not provide comfort...
and could be a source of greater morbidity. The usefulness and tolerability of parenteral fluid replacement and/or parenteral nutrition should be carefully discussed with the patient. For patients at the end of life, parenteral nutrition has shown to be of limited use, as cachexia does not improve with it. Eating should be a pleasant experience for the patient during this period, not a source of stress. In cases where the medical team expects that obstruction can be improved with conservative or palliative surgery, parenteral nutrition for 7-10 days prior to the intervention can reduce postoperative infections, hospital stay, and postsurgical mortality. In such cases, it is a beneficial option for optimizing the patient for the surgery.

**Vaginal bleeding**

Bleeding is a frequent symptom in advanced cervical cancer and may be a cause of death (6%). The current approach depends on the available resources. Interventions for treatment of vaginal bleeding in women with advanced cervical cancer include tranexamic acid, vaginal packing (with or without formalin-soaked packs), interventional radiology (selective embolization) in addition to palliative radiotherapy (when it is feasible). There is no evidence from controlled trials supporting or refuting the use of any of the proposed interventions compared with radiotherapy. In the case of major bleeding, palliative sedation can be considered.

**Malodorous vaginal discharge**

Necrotic tumour often induces malodorous vaginal discharge that can be improved with vaginal washing and the use of a metronidazole tablet intravaginally.

**Renal failure**

Renal failure induced by obstructive nephropathy is common among patients with compressive pelvic advanced tumour and may be the result of end-stage kidney disease. Symptoms such as dyspnea, pruritus, or delirium can appear and exacerbate other symptoms like edema and pain.

Urinary derivation by ureteral stent or percutaneous nephrostomy could be a solution to hydronephrosis when the aim is to prevent the patient from dying from uremia and not from cervical cancer. There are no clear guidelines to exactly predict which patients will benefit from percutaneous nephrostomy in terms of survival and quality of life. A retrospective study suggested that percutaneous nephrostomy can be of clinical benefit for patients with recurrent cervical cancer and good performance status and may prolong survival. However, complications of percutaneous nephrostomy are frequent, including urinary tract infection (20%) and catheter loss (20%), pain induced by the catheter and most patients still die from renal failure. These data highlight the importance of carefully selecting patients who can derive benefit from this procedure. Ascites, poor ECOG, diabetes mellitus, low serum albumin, hyponatremia, malignancy-related events and azotemia have been shown in different studies to result in a bad prognosis for percutaneous nephrostomy.

When it is technically feasible, instead of percutaneous nephrostomy, a ureteral stent is an easier and less invasive procedure. In particular, tandem ureteral stenting has shown better results than a single ureteral stent. In the case of urinary retention, urinary catheter is a good and easy palliative option to provide relief.
**Fistula**

Rectal-vaginal and colon-bladder fistulas are common especially among patients with pelvic relapse after radiotherapy, which can lead to poor quality of life and psychological suffering. In these cases, surgery (colostomy or nephrostomy) can be discussed, but the benefit-risk ratio must be considered in each patient\(^{240}\).

**Cachexia and fatigue**

Cachexia and fatigue are two of the most common symptoms in advanced cervical cancer patients. Dedicated ESMO guidelines describe treatment and management for these symptoms\(^{261,262}\).

**Psychosocial suffering**

Cervical cancer may give rise to the social stigma associated with diseases of the genitals and a malodorous vaginal discharge, which may evoke feelings of humiliation, guilt, or shame. These feelings are related to suffering and loss of faith as well as being able to find meaning in life, which, along with the extreme physical symptoms produce a psychosocially complex environment that makes the multidisciplinary approach towards these patients and their families even more important\(^{254,263,264}\).

Physicians, nurses, psychologists, social workers, and community health workers can and must help to provide appropriate supportive counselling in a multidisciplinary approach. Psycho-oncologists and social workers collaborate with oncologists and palliative care providers to assess the severe, complex, or refractory psychological and social suffering of patients with cancer and their family members. Some standard simple self-reported questionnaires may be used to detect psychosocial distress such as the Distress Thermometer\(^{240,265}\). Non-pharmacologic interventions such as psychotherapy and supportive counselling are important approaches to help manage physical symptoms and improve quality of life.

Apart from the psychosocial circle, spiritual issues are extremely important at the end of life. Medical professionals should take care of this point and provide patients with the resources to access their needs, such as a spiritual guide\(^{239,254}\). In the case of clinically significant depression the use an antidepressant is indicated, especially fluoxetine\(^{254}\). Fluoxetine is one of the most commonly prescribed antidepressants and is proven to be safe, with a low risk of side effects and good tolerance. Its effectiveness in treating depression has been well-documented\(^{254}\).

**Cervical cancer in pregnancy**

Although the majority of cervical cancers coincidentally diagnosed in pregnancy are detected in early stages due to prenatal care, the association between cancer and pregnancy remains a significant challenge between optimal maternal therapy and fetal viability, and the decisions about therapy, taken by a multidisciplinary team, must be individualized. Many studies addressing the management of cervical cancer in pregnant women, mainly retrospective series, have been published in the course of the past 5 years, confirming the validity of the original ESGO/ESTRO/ESP guidelines\(^{266-297}\).

Imaging of pregnant cervical cancer patients as part of the primary work-up is still challenging. Radiologists play an important role in the multidisciplinary team in order to select the most optimal imaging strategies that balance maternal benefit with fetal risk and that are most likely to guide treatment decisions. Due to the absence of radiation exposure and highly accurate clinical performance, expert ultrasound and MRI remain the preferred imaging modalities. MRI has the added advantage of a more reproducible comprehensive organ or body region assessment, the ability of distant staging through whole-body evaluation, and the combination of anatomical and functional information by diffusion-weighted imaging which obviates the need for a gadolinium-based contrast-agent\(^{298}\). WB-DWI/MRI holds...
promise for accurate single-step staging with the absence or reduction of fetal radiation. Because of limited experience and inherent radioactivity, PET-CT should be avoided during pregnancy.

Currently, there is no uniform standard for treatment. Several treatment modalities are available and should be discussed with the patient taking into account the tumour stage, gestational week of pregnancy and patient’s preferences. Depending on tumour stage and gestations age at diagnosis, delay of oncological treatment until fetal maturity (if possible >34 weeks of gestation) and initiate cancer-specific treatment immediately after delivery by cesarean section should be discussed. This option might be considered if the term or fetal maturity is approaching.

Simple trachelectomy and PLND may be an option to be considered in a very select group of patients in order to preserve the pregnancy with the aim of definitive treatment at the time of delivery or shortly thereafter. Abdominal radical trachelectomy may be discussed for selected patients with early-stage cervical cancer who want to preserve their pregnancy and who are not willing to expose the fetus to the risks associated with NACT. Minimal invasive approach could be considered before 14-16 weeks of gestation.

In locally advanced cervical cancer, platinum-based NACT may be offered to patients during the second and third trimesters and wishing to preserve an ongoing pregnancy in order to achieve fetal maturity, treat, stabilize and prevent further dissemination of the disease until the term, decrease the volume and extent of the tumour, and limit LN metastasis and distant micrometastasis during pregnancy. However, long-term consequences of chemotherapy in the child are yet to be determined. Taxanes, when combined with platinum derivatives, may be safely administered in cervical cancer patients during the second and third trimesters of pregnancy, and thus could be an option. Available data are inconsistent with respect to best regimen and maximal number of NACT cycles. Potential risks and benefits of cumulative chemotherapy have to be balanced with possible problems of fetal prematurity.

There are conflicting data with respect to mode of delivery. Occurrence of episiotomy scar recurrence can be associated with negative oncologic outcome. As spontaneous delivery appears to have negative prognostic impact and until more valid data available, cesarean section should be preferred mode of delivery.

If the women decide to not preserve the pregnancy, radical hysterectomy or definitive CTRT should be discussed according to the disease stage as recommended outside pregnancy. Pregnancy termination is recommended before any treatment after the first trimester, and fetus evaluation before CTRT. However, radical hysterectomy with fetus in situ is feasible without increased intra- or postoperative morbidity and does not worse oncologic outcome. Primary CTRT in early pregnancy induces spontaneous abortion and use of misoprostol can simplify uterine evacuation.

**Rare tumours**

This chapter was introduced to provide information on infrequent and uncommon tumour types of the uterine cervix. Due to their infrequency compared to particularly squamous cell carcinoma and adenocarcinoma, the title of “rare tumours” was selected. However, we are aware that this name could also be misleading to some point. The NCI defines rare tumours by an incidence of less than 15/100.000/year. The Joint Action on Rare Cancers of the European Union defines rare cancers those with a crude incidence rate of less than 6/100.000/year. It is important to keep in mind that in many European countries the incidence of cervical carcinoma by itself is less than 1.5, which designates cervical carcinoma generally as a rare tumour. Nonetheless, identifying the rarest within the rare is important, due to the specific expertise needed to diagnose and treat patients affected by rare cervical cancers.
Rare cervical tumours represent a basket of tumours including a variety of epithelial, mesenchymal and other tumours and excluding squamous cell carcinoma and usual adenocarcinomas. It needs to be stressed that these tumours as a whole may affect patients of almost all age groups whereas the incidence of single tumour entities varies between the age groups.

Generally, the amount of scientific evidence for diagnosing and treating rare cervical tumours is limited, for the small number of cases reported. Most published articles are dealing with case reports or case series. Cervical neuroendocrine carcinoma, carcinosarcoma and sarcomas are the tumour types most frequently reported and discussed. In the recent WHO classification, carcinosarcoma is considered a type of carcinoma but it is not uncommon to find it discussed together with sarcomas.

In the National Cancer Database during the period 2004-2015, more than 100,000 new cases of cervical cancer were reported. Of these, squamous cell carcinoma accounted for about 76% and adenocarcinomas for about 23% of the cases. Carcinosarcomas and sarcomas, including leiomyosarcomas, adenosarcomas and rhabdomyosarcomas accounted for most of the remaining approximately 1% of cases.

**Carcinosarcoma**

Carcinosarcomas seem to occur at older age and present at higher stage compared to squamous cell and adenocarcinomas\(^302\). The most common stage at presentation is FIGO IB and stage is the most important independent prognostic factor for recurrence and survival\(^303\). A heterologous component was found in about a third of the cases\(^303\). Lymph node involvement was found in a subset of cases but was not of prognostic value\(^303\). There is no standard therapy for cervical carcinosarcoma, but surgery followed by adjuvant radiotherapy with or without chemotherapy seems to improve overall and disease-free survival\(^303\). Prognosis seems to be better than for carcinosarcomas of the uterine corpus due to earlier symptoms and diagnosis\(^304\). Radical hysterectomy and bilateral salpingo-oophorectomy with pelvic lymphadenectomy and SN detection should be considered as the primary therapeutic modality\(^303,305\).

**Small cell neuroendocrine carcinoma**

The incidence of small cell neuroendocrine carcinoma of the cervix is not clear, even if quite a number of publications can be found in the literature\(^306\). It is likely that small cell neuroendocrine carcinoma accounts for about 2% of all cervical carcinomas. Most tumours are associated with HPV, mainly HPV types 16 and 18\(^307\). The incidence seems to rise during recent years maybe due to increased attention and improved diagnostic knowledge. Small cell carcinoma must be distinguished from poorly differentiated non-keratinizing squamous cell carcinoma and other mimics such as malignant lymphoma, rhabdomyosarcoma and undifferentiated carcinoma\(^308\). In a subset of cases patients may present with clinical and/or biochemical evidence of ectopic hormone production such as corticotropin, vasopressin, insulin, insulinoma-associated protein (INSM1), serotonin or parathormone and the related syndrome. A retrospective study on 93 small cell carcinomas of the cervix at stages I and II revealed invasion of lymphovascular spaces as a significant prognostic factor for both overall survival and disease-free survival and PLN metastasis and adjuvant chemotherapy with etoposide/cisplatin or irinotecan/cisplatin regimen as prognostic factors for disease-free survival\(^309\). A large study from China showed that advanced FIGO stage, large tumour size and older age were independent prognostic factors for overall survival whereas FIGO stage, tumour size and para-aortic LN metastasis were independent prognostic factors for progression-free survival\(^310\). Another large study from China revealed that LN status (p<0.01) and cancer directed surgery (p<0.01) were independent prognostic factors for FIGO I-IIA stage tumours whereas age (p<0.05), tumour size (p<0.01), chemotherapy (p<0.01) and radiation (p<0.01) were independent prognostic factors for FIGO stages IIIB-IV\(^311\). In FIGO stages IB1-IIA1 treated with initial surgery, LN metastasis and resection margin involvement were poor prognostic factors of survival\(^312\). FIGO stage IVB seems to be exclusively associated with poor prognosis\(^313\). A meta-analysis showed FIGO staging, tumour size, parametrial involvement, resection margin, depth of stromal invasion, and LN metastasis as predictors of prognosis\(^314\). On the molecular level, neuroendocrine carcinoma of the cervix seems to be
distinct from its counterpart in the lung and the urinary bladder by a significantly lower rate of coding mutations and TP53 mutations. In fact, PI3-kinase or MAPK pathway activating mutations were found in 67% of neuroendocrine carcinoma of the cervix. These findings suggest that on the molecular level neuroendocrine carcinomas of the cervix seem to be more similar to usual cervical carcinomas than to extra-cervical neuroendocrine carcinomas, particularly of lung and bladder315. Small cell neuroendocrine carcinomas are microsatellite stable but the data on PD-L1 expression are controversial with reported positivity in up to 50% of the cases316,317. Immunoreactivity for PARP-1 suggests a possible response to therapeutic PARP inhibition, but there is currently no information on a potential value of molecular alterations in this perspective, particularly of BRCA1/2 mutations or homologous recombination deficiency316. About a third of the cases seem to be immunoreactive for N-TRK but lack gene fusions317.

Evidence on treatment of neuroendocrine carcinoma is limited and standard therapy is lacking318,319. Radical surgery followed by chemotherapy may be a favorable alternative intervention for selected patients with advanced stage cancer314. NACT and adjuvant chemotherapy but not adjuvant radiotherapy seems to improve prognosis320. Paclitaxel plus cisplatin or paclitaxel plus carboplatin may be an alternative to etoposide/cisplatin, that remains the standard chemotherapy regimen used by most authors306,314.

Immune checkpoint inhibitor therapy is promising but lacks controlled evidence318. A multi-institutional retrospective analysis including 166 patients from 13 hospitals in Korea considered local radiotherapy as a definitive choice of treatment, particularly for advanced stage disease321. A systematic review including 11 studies with a total of 27 cases revealed that surgery after NACT may yield similar outcomes for locally advanced neuroendocrine carcinomas compared to CTRT322. The benefit of performing surgery as a primary approach could lie in the possibility of reserving CTRT for recurrences322. The need for effective systemic therapy is endorsed321.

**HPV-independent adenocarcinoma, clear cell type**

A retrospective study on clear cell carcinoma of the cervix includes 47 cases without exposure to diethylstilbestrol at a median age of 52 years323. About 50% percent of the cases presented at stage I. Almost 90% of the cases underwent radical hysterectomy and pelvic lymphadenectomy323. Within a multimodal approach, surgery seems to be effective in cases amenable to complete resection323. Advanced tumour stage, larger tumour size and PLN metastasis had negative effects on progression-free survival and overall survival. Adjuvant radiation therapy alone or concurrent CTRT after radical surgery did not affect survival in patients with risk factors323.

**Sarcomas**

Like carcinosarcomas, sarcomas seem to occur at older age and seem to present at higher stage compared to squamous cell and adenocarcinomas302. Leiomyosarcomas, adenosarcomas and rhabdomyosarcomas are the most frequently reported histological types, in addition a sarcoma NOS category has been reported302.

A meta-analysis on leiomyosarcomas (including 42 cases published in 29 articles) revealed age (< 48 years) and mitotic count (< 10/10 HPF) as independent prognostic factors for recurrence and age and performed hysterectomy as independent prognostic factors for survival324. Hysterectomy, without preference of radical hysterectomy, is considered the treatment of choice. Due to the rarity of this tumour, therapy mostly follows the treatment modalities for the more frequent uterine corpus counterpart324.

A single centre study on 49 adenosarcomas (19 from the cervix, 30 from the corpus) showed that disease-free survival was associated with tumour location, presence of a stalk connecting the tumour to cervix or corpus, heterologous elements and invasion of lymphovascular space325. In multivariate analysis, presence of tumour stalk remained an independently protective factor for recurrence and invasion of lymphovascular space a risk factor for recurrence325.
References


32. Pedone Anchora, L., *et al.* Should the Number of Metastatic Pelvic Lymph Nodes be Integrated into the 2018 Figo...


96. Lecuru, F.R., et al. SENTICOL III: an international validation study of sentinel node biopsy in early cervical cancer. A GINECO, ENGOT, GCIG and


165. Ekdahl, L., *et al.* A combination of second trimester oral metronidazole and no sexual intercourse during second and


194. Pergialiotis, V., *et al.* The impact of adjuvant hysterectomy on survival outcomes of patients with locally advanced cervical cancer: A network


242. Ertas, I.E., et al. The effectiveness of subcutaneously implanted epidural ports for relief of severe pain in patients with advanced-stage gynecological...


292. Terukina, J., Takamatsu, M., Enomoto, T. & Baba, H. Anesthetic management of abdominal radical trachelectomy for...


APPENDIX 1. IDENTIFICATION OF SCIENTIFIC EVIDENCE

<table>
<thead>
<tr>
<th>Language</th>
<th>Study design</th>
</tr>
</thead>
<tbody>
<tr>
<td>English</td>
<td>Priority was given to high-quality systematic reviews and meta-analyses but lower levels of evidence were also evaluated. The search strategy excluded editorials, letters, case reports and in vitro studies</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Research period</th>
<th>Indexing terms</th>
</tr>
</thead>
<tbody>
<tr>
<td>2017/01/01 - 2022/03/01</td>
<td>5-fluorouracil, abdominal trachelectomy, abdominal radical trachelectomy, adenocarcinoma, adenocarcinoma, basal cervical carcinoma, adenocarcinoma, cervical carcinoma, adenocarcinoma, cervical carcinoma, adenocarcinoma, cervical carcinoma, advanced cervical cancer, advanced cervical carcinoma, advanced cervical disease, advanced disease, advanced stage, atypical cervical carcinoma, atypical carcinoma tumour, basaloid cervical carcinoma, basaloid cystic carcinoma, basaloid cervical carcinoma, bevacizumab, biomarker, biopsy, bladder involvement, bleomycin, brachytherapy, brachytherapy boost, cancer antigen 125, cancer antigen 15-3, carboptatin, carcinoembryonic antigen, carcinosarcoma, cemiplimab, cervical adenoid-basal cervical carcinoma, cervical adenoid cystic carcinoma, cervical atypical carcinoma tumour, cervical cancer, cervical carcinoma, cervical carcinoma, cervical clear cell carcinoma, cervical high-grade neuroendocrine carcinoma, cervical low grade neuroendocrine tumour, cervical mixed large cell neuroendocrine carcinoma, cervical mucinous carcinoma, cervical mucinous tumour, cervical small cell carcinoma, cervical sarcoma, cervical sarcomatous tumour, cervical small cell neuroendocrine carcinoma, cervical stromal invasion, cervical stromal involvement, cervical typical carcinoid tumour, cervix cancer, cervix uteri, chemotherapy, circulating immune complexes, cisplatin, cis-diaminedichloroplatinum, cis-platinum, clear cell carcinoma, clear cell type, clear margin, clinical staging, clinical trial, clinicaltrials.gov, combined large cell neuroendocrine carcinoma, combined positive score, combined small cell neuroendocrine carcinoma, complications, computed tomography, cone biopsy, cone resection, cone resection margins, conization, cryopreservation, cystoscopy, cytokeratin fragment 21-1, cytology, definitive treatment, diagnostic workup, destructive techniques, early cervical cancer, early cervical carcinoma, early cervical disease, early disease, early stage, endovaginal ultrasound, endometrioid adenocarcinoma, excision, excisional techniques, external beam radiation therapy, external beam radiotherapy, extracervical tumour extension, fertility, fertility outcome, fertility preservation, fertility sparing, fertility sparing management, fertility sparing surgery, fertility sparing treatment, FIGO, FIGO staging system, follicular dendritic cell sarcoma, follow-up, follow-up procedures, follow-up protocols, frozen sections, germ cell tumour, gestation, high-grade neuroendocrine carcinoma, high sensitivity C-reactive protein, human papillomavirus-independent adenocarcinoma, human papillomavirus testing, hysterectomy, hysterectomy specimen, image guided adaptive brachytherapy, image guided radiotherapy, imaging, imaging modalities, imaging procedure, imaging text, immunosuppressive acidic protein, intensity modulated radiotherapy, intensive care, intensive care unit, interlink 6, invasive cervical cancer, invasive cervical carcinoma, invasive cervical disease, invasive disease, invasive stage, isolated tumour cell, laparoscopic staging, laparoscopy, laparotomy, large cell neuroendocrine carcinoma, large loop excision of the transformation zone, laser ablation, laser ablation-destruction, laser conization, laser conization-excision, laser destruction, length of stay, leiomyosarcoma, local clinical diagnostic workup, local diagnostic workup, locally advanced cervical cancer, locally advanced cervical carcinoma, locally advanced disease, locally advanced stage, long-term survivorship, loop conization, loop electrosurgical excision procedure, low grade neuroendocrine tumour, lymphadenectomy, lymph node, lymph node assessment, lymph node dissection, lymph node staging, lymphovascular space involvement, macroaggregates, magnetic resonance imaging, malignant intestinal obstruction, malignant lymphoma, margin status, mature teratoma, mesonephric type, metastatic cervical cancer, metastatic cervical carcinoma, metastatic cervical disease, metastatic disease, microinvasive cancer, microinvasive cervical cancer, microaggregates, mixed large cell neuroendocrine carcinoma, mortality rate, mortality analysis, mucinous carcinoma, mucinous tumour, mucosideroid carcinoma, multidisciplinary board, multidisciplinary setting, multidisciplinary team, multivariate analysis, myeloid sarcoma, neoadjuvant chemotherapy, neoadjuvant treatment, neonatal intensive care unit admission, nerve-sparing radical surgery, nerve-sparing robotic radical hysterectomy, nodal involvement, non-gestational chorionicarcinoma, obstetric outcomes, obstetric risk, occult carcinoma, occult invasive carcinoma, occult invasive cervical cancer, occult cervical cancer, oncologic outcome, oncologic risk, ovarian preservation, ovarian transplantation, ovarian transposition, oxaliplatin, paclitaxel, pain, palliative care, palliative chemotherapy, palliative management, palliative radiotherapy, palliative setting, palliative surgery, palliative systemic treatment, palliative treatment, paraaortic lymphadenectomy, paraaortic lymph node assessment, paraaortic lymph node dissection, parametrial resection, pathological analysis, pathological evaluation, pathological staging, pathology, pathology report, pathology report adequacy, patient-reported outcome, pelvic examination, pelvic lymph node assessment, pelvic lymph node dissection, pelvic lymphadenectomy, peripheric care, physical destruction, platinum, platinum-based chemotherapy, platinum emission tomography, positron emission tomography/computed tomography, postoperative care, postoperative complications, postoperative recurrence, pregnancy, pretreatment spontaneous rupture of membranes, preoperative brachytherapy, pregnancy, pregnancy outcome, pregnancy rate, pregnant patient, preoperative care, preoperative work-up, preoperative work-up, pure small cell carcinoma, quality of health care, quality of life, radiation therapy, radical abdominal trachelectomy, radical cervical cancer, radical cervical surgery, radical cervical tumor, radical cervical tumor, radical cervical trigonothesis, radiochemotherapy, radiological staging, radiotherapy, rare tumour, rare cervical cancer, rare cervical disease, rare cervical tumour, rare tumour, rectal cancer, rectal disease, rectal tumour, rectoscope, rectoscopy, recurrent cervical cancer, recurrent disease, recurrence, reproducibility, reproductive techniques, residual disease, residual tumour, restaging, rhabdomyosarcoma, risk factors, robotic radical hysterectomy, sampling, sarcoma, sarcomatous tumour, sensitivity, sentinel lymph node, sentinel lymph node dissection, sentinel lymph node procedure, sentinel node, serum biomarker, serum marker, simple hysterectomy, simple hysterectomy specimen, specificity, simple trachelectomy, small cell neuroendocrine carcinoma, specialized center, specimen grossing, squamous cell carcinoma antigen, staging, staging procedures, stromal invasion, stromal involvement, supportive care, supportive care, supportive management, supportive setting, supportive treatment, surgery, surgical lymph node assessment, surgical management, surgical margin, surgical outcome, surgical outcome criteria, surgical procedures, surgical resection, surgical staging, surveillance, survival rate, survival analysis, survivorship, terminal illness, terminal illness, terminal patient, tissue polypeptide antigen, TNM, TNNM classification, total laparoscopic radical trachelectomy, trachelectomy, transplantation, transposition, transrectal ultrasound, treatment outcome, tumour-associated tryptase inhibitor, tumour necrosis factor alpha, typical carcinoid tumour, undifferentiated carcinoma, ultraguided trachelectomy, ultrasound, upstaging, urethra, uterine transplantation, vaginal radical trachelectomy, vaginal trachelectomy, vascular space involvement, vascular endothelial growth factor, vincristine, yolk sac tumour.</td>
</tr>
</tbody>
</table>
APPENDIX 2. LIST OF THE 155 EXTERNAL REVIEWERS

Jafaru Abu, gynaecological oncologist (United Kingdom); Jasimu Umar Adoke, pathologist (Nigeria); Hoda Al-booaz, clinical oncologist (United Kingdom); Giovanni Alettì, gynaecological oncologist (Italy); Roberto Altamirano, gynaecological oncologist (Chile); Igor Alulski, gynaecological oncologist (Republic of North Macedonia); Frédéric Amant, gynaecological oncologist (Belgium); Beatrice Anghel, radiation oncologist (Romania); Mairit Anttila, gynaecological oncologist (Finland); Ali Ayhan, gynaecological oncologist (Turkey); Paloma Badia Agustì, gynaecological oncologist (Spain); Elena Bakhidze, gynaecological oncologist (Russia); Joost Bart, pathologist (Netherlands); Anne-Sophie Bats, gynaecological oncologist (France); Mario Beiner, gynaecological oncologist (Israel); Virginia Benito, gynaecological oncologist (Spain); Kamil Bringer, obstetrician gynaecologist (Slovakia); Mazen Bishawi, gynaecological oncologist (Qatar); Nicolò Bizzarri, gynaecological oncologist (Italy); Tatjana Bozanovic, gynaecological oncologist (Serbia); Kjersti Bruheim, clinical oncologist (Norway); Ewa Burchardt, radiation oncologist (Poland); Marta Caretto, gynaecological oncologist (Italy); Supriya Chopra, radiation oncologist (India); Nicoletta Colombo, gynaecological oncologist (Italy); Nicole Concin, gynaecological oncologist (Austria); Abel Cordoba, radiation oncologist (France); Sofia Córdoba Largo, radiation oncologist (Spain); Stefanie Corradini, radiation oncologist (Germany); Sabrina Croce, pathologist (France); Branko Cvjetičanin, gynaecological oncologist (Serbia); Alessandro D’Amuri, pathologist (Italy); Ademi Dafina, clinical oncologist (Kosovo); Kreshnike Dedushi-Hoti, radiologist (Kosovo); Anne de Middelaer, patient (Belgium); Vitaliana De Sanctis, radiation oncologist (Italy); Kalyan Dhar, gynaecological oncologist (United Kingdom); Antonio Ditto, gynaecological oncologist (Italy); Beth Erickson, radiation oncologist (United States of America); Brynhildur Eyjolfsdottir, gynaecological oncologist (Iceland); Anna Fagotti, gynaecological oncologist (Italy); Henrik Falconer, gynaecological oncologist (Sweden); Daniela Fanni, pathologist (Italy); Angelica Viviana Fletcher, gynaecological oncologist (Turkey); Christina Fotopoulos, gynaecological oncologist (United Kingdom); Cristina Frutuoso, gynaecological oncologist (Portugal); Prafull Ghatage, gynaecological oncologist (Canada); Antonio Gil-Moreno, gynaecological oncologist (Spain); Frédéric Goffin, gynaecological oncologist (Belgium); Francois Gollier, obstetrician gynaecologist (France); Mikel Gorostidi, obstetrician gynaecologist (Spain); Deborah Gregory, clinical oncologist (United Kingdom); Benedetta Guani, gynaecologist (Switzerland); Emons Günter, gynaecological oncologist (Germany); Frédéric Guyon, gynaecological oncologist (France); David Hardisson, pathologist (Spain); Annette Hasenburg, obstetrician gynaecologist (Germany); Kristina Hellman, medical oncologist (Sweden); Gines Hernandez-Cortes, obstetrician gynaecologist (Spain); Antonio Herreros, medical oncologist (Spain); Peter Hoskin, clinical oncologist (United Kingdom); Kim Hulscher, patient (Netherlands); Vlora Ibishi, gynaecologist (Kosovo); Ahmet Cem Ilybozkurt, gynaecological oncologist (Turkey); Nina Boje Kiibsgaard Jensen, clinical oncologist (Denmark); Kate Johnson, radiation oncologist (Canada); Ina Jürgenliemk-Schult, radiation oncologist (Netherlands); Ioannis Kalogiannidis, gynaecological oncologist (Greece); Vesna Kesic, gynaecological oncologist (Serbia); Pearly Khaw, radiation oncologist (Australia); Gurkan Kiran, gynaecological oncologist (Turkey); Kathrin Kirchheiner, radiation oncologist (Austria); Christian Kirschits, radiation oncologist (Austria); Manon Kissel, radiation oncologist (France); Marko Klarić, gynaecological oncologist (Croatia); Roman Kocijan, gynaecological oncologist (Czech Republic); Gunnar Kristensen, gynaecological oncologist (Norway); Kersti Kukk, gynaecological oncologist (Estonia); Valentina Lancellotta, radiation oncologist (Italy); Fabio Landoni, gynaecologist (Italy); Gabriel Lindahl, gynaecological oncologist (Sweden); Kristina Loesel, radiation oncologist (Switzerland); Tiziano Maggino, gynaecological oncologist (Italy); Katarina Majercakova, radiation oncologist (Spain); Saadia Mameri, pathologist (Algeria); Aljosa Mandic, gynaecological oncologist (Serbia); Suzana Manxhuka-Kerliu, pathologist (Kosovo); Bogdan Margineanu, obstetrician gynaecologist (France); Fabio Martinelli, gynaecological oncologist (Italy); Claudia Mateoiu, pathologist (Spain); Xavier Matias-Guiu, gynaecological oncologist (Israel); Eva Meixner, radiation oncologist (Germany); Lucas Mendez, radiation oncologist (Canada); Miloš Mlynček, gynaecological oncologist (Slovakia); David Alejandro Moralez Fernandez, gynaecological oncologist (Spain).
oncologist (Colombia); Philippe Morice, gynaecological oncologist (France); Esten Nakken, radiation oncologist (Norway); Peter Niehoff, radiation oncologist (Germany); Eva-Maria Nine-Roolah, oncological gynaecologist (Estonia); Krzysztof Nowosielski, gynaecological oncologist (Poland); Ernst Oberlechner, gynaecological oncologist (Germany); Claudia Ordeanu, radiation oncologist (Romania); Coza Ovidiu Florin, radiation oncologist (Romania); Saulius Paskauskas, gynaecological oncologist (Lithuania); Anna Myriam Perrone, gynaecological oncologist (Italy); Elisabetta Perrucci, radiation oncologist (Italy); Patrick Petignat, obstetrician gynaecologist (Switzerland); Stamatis Petousis, gynaecological oncologist (Greece); Primoz Petric, radiation oncologist (Switzerland); Bradley Pieters, radiation oncologist (Netherlands); Radovan Pilka, obstetrician gynaecologist (Czech Republic); Richard Poetter, radiation oncologist (Austria); Mario Preti, gynaecologist (Italy); Anna Protasova, gynaecological oncologist (Russia); Isabelle Ray-Coquard, medical oncologist (France); Nicholas Reed, clinical oncologist (United Kingdom); Alexander Reinthaller, gynaecological oncologist (Austria); Sophie Renard, radiation oncologist (France); Ángeles Rovirosa, radiation oncologist (Spain); Vilius Rudaitis, gynaecological oncologist (Lithuania); Giovanni Scambia, gynaecological oncologist (Italy); Sergio Schettini, gynaecologist (Italy); Jalid Sehouli, gynaecological oncologist (Germany); Cristiana Sessa, gynaecological oncologist (Switzerland); Paul Sevelda, gynaecological oncologist (Austria); Philippe Simon, gynaecological oncologist (Belgium); Tayup Simsek, gynaecological oncologist (Turkey); Piero Sismondi, obstetrician gynaecologist (Italy); Tone Skeie-Jensen, gynaecological oncologist (Norway); Špela Smrkolj, gynaecological oncologist (Slovenia); Erik Soegaard-Andersen, obstetrician gynaecologist (Denmark); Sofia Spampinato, medical physics (Denmark); Hana Stankusova, radiation oncologist (Czech Republic); Simona Stolnicu, pathologist (Romania); Eva-Maria Strömsholm, patient (Finland); Alina Sturdza, radiation oncologist (Austria); Sudha Sundar, gynaecological oncologist (United Kingdom); Jacek Jan Sznurkowski, gynaecological oncologist (Poland); Li Tee Tan, clinical oncologist (United Kingdom); Ekkasit Tharavichitkul, radiation oncologist (Thailand); Tayfun Toptas, gynaecological oncologist (Turkey); Antonio Travaglino, pathologist (Italy); Helen Trihia, pathologist (Greece); Elena Ulrikh, gynaecological oncologist (Russia); Margit Valgma, radiation oncologist (Estonia); Jacobus van der Velden, gynaecological oncologist (Netherlands); Ignace Vergote, gynaecological oncologist (Belgium); René Verheijen, gynaecological oncologist (France); Lisa Vicenzi, radiation oncologist (Italy); Nadia Villena Salinas, pathologist (Denmark); Boris Vranex, gynaecological oncologist (Serbia); Henrike Westerveld, radiation oncologist (Netherlands); Nuri Yildirim, gynaecological oncologist (Turkey); Gian Franco Zannoni, pathologist (Italy).